Document:

Employment Agreement Between Xcyte and Joanna Lin Black

 Exhibit 10.40 
  
 XCYTE THERAPIES, INC. 
  
 EMPLOYMENT AGREEMENT 
  
 This Employment Agreement (the “Agreement”) is dated as of December 31, 2001 (the “Effective Date”), by and between
Joanna S.L. Black (“Employee”) and Xcyte Therapies, Inc., a Delaware corporation (the “Company”), and sets forth the terms and conditions with respect to Employee’s employment with the Company as
of and after the date of this Agreement. 
  
 1.
Duties. 
  
 (a) Position
Responsibilities. Employee shall be employed as General Counsel and Director of Business Development of the Company commencing January 28, 2002 (the “Start Date”). The duties and responsibilities of Employee shall include
the duties and responsibilities as attached hereto as Attachment A and such other duties and responsibilities as the Chief Executive Officer or the Chief Business Officer may from time to time reasonably assign to Employee, in all
cases to be consistent with Employee’s corporate office and position. 
  
 (b) Obligations to the Company. Employee agrees to the best of her ability and experience that she will at all times faithfully perform all of the duties and obligations required of and from Employee,
consistent and commensurate with Employee’s position, pursuant to the terms hereof. During the term of Employee’s employment relationship with Company, Employee will not directly or indirectly engage or participate in any business that is
competitive in any manner with the business of Company, as a director, officer, advisor or contractor or in any other capacity with respect to any such competitive business. Nothing in this Agreement will prevent Employee from (i) making personal
investments in, and sitting on the board of directors or board of advisors of, businesses that are not competitive with the business of Company, or (ii) accepting speaking or presentation engagements in exchange for honoraria or from serving on
boards of charitable organizations, provided that such activities listed in (i) and (ii) do not materially interfere with Employee’s obligations to Company as described above. Nothing in this Agreement will require Employee to divest of passive
investments made prior to this Agreement in a business that is or may be competitive with the business of the Company or from making similar investments in the future provided that Employee is no longer employed by the Company. Employee will comply
with and be bound by Company’s operating policies, procedures and practices from time to time in effect during the term of Employee’s employment. 
  
 2. Confidentiality Agreement. On or prior to the Start Date, Employee shall sign a Proprietary Information and Invention Assignment
Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto as Attachment B. Employee hereby represents and warrants to Company that she has complied with all obligations under the
Confidentiality Agreement since the commencement of discussions with the Company regarding employment and agrees to continue to abide by the terms of the Confidentiality Agreement and further agrees that the provisions of the Confidentiality
Agreement shall survive any termination of this Agreement or of Employee’s employment relationship with Company. 

 3. Compensation. 
  
 (a) Salary. Employee shall receive a monthly salary of $12,500 (subject to applicable withholding taxes),
which is equivalent to $150,000 on an annualized basis (the “Base Salary”). Employee’s monthly salary will be payable pursuant to the Company’s normal payroll practices. 
  
 (b) Stock Options. The Company will recommend to the Board of
Directors of the Company that, at the next Board meeting, following the Employee’s Start Date, Employee be granted an option to purchase 50,000 shares of the Company’s Common Stock (“Shares”) with an exercise price equal
to the fair market value on the date of the grant and a vesting schedule as follows: subject to Employee’s continued active full-time employment with the Company, 25% of the Shares shall vest on the date that is the one year anniversary of the
Vesting Commencement Date (defined by reference to the Employee’s Start Date) and an additional 1/48th of the
Shares shall vest monthly thereafter until all Shares have vested (total vesting in 48 months), with such additional vesting on Change of Control, as that term is defined in the Company’s 2000 Stock Option Plan (the “Stock Option
Plan”) as is determined by the Board at the time of grant. The option will be an incentive stock option to the maximum extent allowed by the Internal Revenue Code of 1986, as amended, and will be subject to the terms of the Stock Option
Plan and the Stock Option Agreement between Employee and the Company. 
  
 4. Benefits. 
  
 (a) General
Benefits. Employee will be eligible to participate in the Company’s employee benefit plans of general application in accordance with the rules established for individual participation in any such plan and under applicable law. Employee
will be eligible for such other benefits as the Company generally provides to its other employees of comparable position. 
  
 (b) Vacation. Employee will be eligible to accrue up to 12 days paid vacation in the first year of service, and 1 additional day per year of
service for a maximum accrual of 17 days paid vacation per year, on a pro-rated accrual basis throughout each calendar year, which accrued vacation may be used in the year in which accrued or in a subsequent year, subject to the Company’s
policies with respect to maximum accrual of unused vacation. 
  
 5. Term; At-Will Employment. The employment of Employee under this Agreement shall be for an unspecified term. The Company and Employee acknowledge and agree that Employee’s employment is and shall continue to be at-will,
as defined under applicable law, and that Employee’s employment with the Company may be terminated by either party at any time for any or no reason, and with or without notice. If Employee’s employment terminates for any reason, Employee
shall not be entitled to any payments, benefits, damages award or compensation other than as provided in this Agreement. 
  
 6. Separation Benefits. Employee shall be entitled to receive separation benefits upon termination of employment only as set forth in this
Section 6; provided, however, that in the event Employee is entitled to any severance pay under a Company-sponsored severance pay plan, any such severance pay to which Employee is entitled under such severance pay plan shall reduce the amount of
severance pay to which Employee is entitled pursuant to this Section 6. In 
  

 2 

 all cases, upon termination of employment Employee will receive payment for all salary and unused vacation accrued as of
the date of Employee’s termination of employment and Employee’s benefits will be continued under the Company’s then existing benefit plans and policies in accordance with such plans and policies in effect on the date of termination
and in accordance with applicable law. 
  
 (a) Voluntary
Resignation. If Employee voluntarily elects to terminate Employee’s employment with the Company, Employee shall not be entitled to any severance benefits. 
  
 (b) Termination for Cause. If the Company or its successor terminates Employee’s employment for Cause,
then Employee shall not be entitled to receive any separation benefits. 
  
 (c) Involuntary Termination. If Employee’s employment is terminated by the Company or its successor under circumstances that constitute an Involuntary Termination, provided Employee signs a general release of claims in
the form attached hereto as Attachment C, she shall receive (i) continued payment of her base salary until the date that is three (3) months from Employee’s Involuntary Termination, subject to applicable withholding taxes, and paid in
accordance with the Company’s normal payroll schedule commencing after Employee’s execution of the general release of claims, and (ii) reimbursement for her expenses incurred in continuing her medical insurance for herself and her
dependents under the Consolidated Omnibus Budget Reconciliation Act of 1984, as amended (“COBRA”), as applicable, for a period of three (3) months following the commencement of such COBRA continuation coverage, provided Employee makes a
timely election for and continues to be eligible for such continued coverage. 
  
 (d) Termination by Reason of Death or Disability. In the event that Employee’s employment with the Company terminates as a result of Employee’s death or her inability to perform the essential
functions of her position with or without reasonable accommodation on account of a mental or physical disability, Employee or Employee’s estate or representative, as applicable, will receive all salary and unpaid vacation accrued as of the date
of Employee’s employment termination and any other benefits payable under the Company’s then existing benefit plans and policies in accordance with such plans and policies in effect on the date of termination and in accordance with
applicable law. 
  
 (e) Definition of “Involuntary
Termination”. For purposes of this Agreement, Employee shall be considered to have been terminated under circumstances that constitute Involuntary Termination if she is terminated by the Company or its successor without Cause (other
than on account of death or disability). 
  
 (f) Definition
of “Cause”. For purposes of this Agreement, “Cause” for Employee’s termination will exist at any time after the happening of one or more of the following events: 
  

 3 

 (i) Employee’s failure to cure, within 30 days after written notice thereof from the Company, her
failure to substantially perform her duties hereunder or gross negligence in the performance thereof, or failure to follow Company policy as set forth from time to time or to follow the legal directives of the Company’s Chief Executive Officer,
so long as such directives are not inconsistent with the Employee’s position and duties and this Agreement; 
  
 (ii) Employee’s act of fraud or embezzlement, or of dishonesty or other misconduct that materially damages the Company, including conviction of a
felony; 
  
 (iii) Employee’s incurable willful breach of any
material provision of the Confidentiality Agreement (as defined in Section 2 above), including without limitation, Employee’s theft or other misappropriation of the Company’s proprietary information. 
  
 7. Conflicts. Employee represents that her performance of all
the terms of this Agreement will not breach any other agreement to which Employee is a party. Employee has not, and will not during the term of this Agreement, enter into any oral or written agreement in conflict with any of the provisions of this
Agreement. 
  

 4 

 8. Successors and Assigns. The rights and obligations under this Agreement shall benefit
and be binding on any successor and/or assign of the Company, and the Company shall cause such successor and/or assign to agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would
be required to perform such obligations in the absence of a succession. The terms of this Agreement and all of Employee’s rights hereunder shall inure to the benefit of, and be enforceable by, Employee’s personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees and legatees. Employee’s obligations under this Agreement may not be assigned. 
  
 9. Miscellaneous Provisions. 
  
 (a) No Duty to Mitigate. Employee shall not be required to mitigate the amount of any payment contemplated by this Agreement (whether by
seeking new employment or in any other manner), nor, except as otherwise provided in this Agreement, shall any such payment be reduced by any earnings that Employee may receive from any other source. 
  
 (b) Amendments and Waivers. Any term of this Agreement may be
amended or waived only with the written consent of the parties. 
  
 (c) Sole Agreement. This Agreement, including any Attachments hereto, constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings with respect to the subject matter hereof. 

 
 (d) Notices. Any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or by a nationally-recognized delivery service (such as Federal Express or UPS), or 48 hours after being deposited in the U.S. mail as certified or
registered mail with postage prepaid, if such notice is addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice. 
  
 (e) Choice of Law. The validity, interpretation, construction
and performance of this Agreement shall be governed by the laws of the State of Washington, without giving effect to the principles of conflict of laws. 
  
 (f) Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to
renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 
  

(g) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
will constitute one and the same instrument. 
  

 5 

 (h) Advice of Counsel. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN EXECUTING THIS
AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE
DRAFTING OR PREPARATION HEREOF. 
  
 The parties have executed this
Agreement the date first written above. 
  

	XCYTE THERAPIES, INC.
	
	 By: /S/ Ronald J. Berenson

	
	 Title: President & CEO

		
	 Address:
	 	1124 Columbia Street, Suite 130
Seattle, Washington 98104

  

	JOANNA S. L. BLACK
		
	 Signature:
	 	 /S/ Joanna S. L. Black

		
	 Address:
	 	 1222 Kirkland Avenue
 Kirkland, Washington 98033

  

 6 

 ATTACHMENT A 
  
 XCYTE THERAPIES, INC. 
 POSITION DESCRIPTION 
  
 Date: December 31,
2001 
  

	 Position Title:
	    	General Counsel and Director Business Development
	 Position Status:
	    	Full-time; Exempt
	 Reports to:
	    	Chief Business Officer

  
 This organization believes that each
employee makes a significant contribution to our success. That contribution should not be limited by the assigned responsibilities. Therefore, this position description is designed to outline primary duties, qualifications and job scope, but not
limit the incumbent nor the organization to just the work identified 
  
 Primary Responsibilities: 
  

	•	Establish the Company’s legal department, including developing procedures for review and filing of contracts and other legal documents. 

  

	•	Manage outside patent counsel and all intellectual property, licensing, patent filing and prosecution related matters. 

  

	•	Manage outside regulatory counsel and all regulatory and clinical legal matters. 

  

	•	Manage outside corporate counsel and all legal issues relating to corporate securities, employment, stockholders, the board of directors, and litigation. 

 

	•	Draft, negotiate and act as a strategic advocate on behalf of the Company in its business development endeavors. 

  

	•	Take an active role in any initial public offering activities of the Company. 

  

	•	Other reasonable duties assigned by the Chief Business Officer. 

 ATTACHMENT C 
  
 GENERAL RELEASE OF CLAIMS 
  
 This General Release of Claims is made by and between
                     (“Employee”) and Xcyte Therapies, Inc., a Delaware corporation (the
“Company”). 
  
 Whereas, in consideration for and
contingent upon Employee’s release of claims as set forth below, the Company has agreed to provide certain separation benefits to Employee in connection with her termination of employment as set forth in the Employment Agreement between
Employee and the Company dated             , 2001 (the “Separation Benefits”); and 
  
 Whereas, Employee acknowledges and agrees that she is not entitled to any severance payment or separation benefits from the
Company other than the Separation Benefits and that she is entitled to the Separation Benefits only upon the Release Effective Date of this General Release of Claims; and 
  
 Whereas, Employee desires to mutually release the Company and related parties from claims as set forth below; 
  
 Employee agrees that the Separation Benefits represents settlement in full of
all outstanding obligations owed to Employee by the Company with respect to Employee’s employment relationship with the Company and the termination of such relationship. Employee, on behalf of himself and her heirs, executors, representatives,
agents, attorneys, successors and assigns, hereby fully and forever releases the Company and its officers, directors, employees, shareholders, agents, attorneys, subscribers, investors, affiliates, predecessors, successors and assigns (hereinafter,
“Xcyte Therapies”) from any claim, duty, obligation or cause of action relating to any matters of any kind, whether known or unknown, suspected or unsuspected, that she may possess arising from any omissions, acts or facts that have
occurred up until and including the date Employee signs this Agreement including, without limitation: 
  
 (a) any and all claims relating to or arising from Employee’s employment with the Company or its successor and termination of that employment;

  
 (b) any and all claims under Title VII of the Civil Rights Act
of 1964, as amended, the Fair Labor Standards Act, the Equal Pay Act of 1963, the Americans With Disabilities Act, the Civil Rights Act of 1991, and Chapter 49.60 of the Revised Code of Washington or any other state and federal laws and regulations
relating to employment or employment discrimination; 
  
 (c) any
and all claims for wrongful termination of employment, breach of contract, breach of a covenant of good faith and fair dealing, violation of public policy, misrepresentation, emotional distress, interference with contract or prospective economic
advantage, and defamation; 
  
 (d) any and all claims relating to,
or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company; 

 (e) any and all claims, including, but not limited to, the Employee Retirement Income Security Act of
1974, as amended (“ERISA”) related to severance benefits; and 
  
 (f) any and all claims for attorney’s fees and costs. 
  
 Employee and the Company agree that the release set forth herein shall be and remain in effect in all respects as a complete and general release as to the matters released. This release does not extend to Employee’s right to vested
benefits (other than severance pay) under any Company-sponsored benefit plan covered by ERISA. 
  
 Employee agree that she will not assist, encourage, institute or cause to be instituted the filing of any administrative charge or legal proceeding against the Company relating to employment discrimination.

  
 Employee and the Company agree that nothing contained in this
Release shall constitute or be treated as an admission of wrongdoing by Employee or the Company. 
  
 Employee agrees that at all times in the future she will continue to be bound by the terms and conditions set forth in the Proprietary Information and
Invention Assignment Agreement between Employee and the Company executed in connection with the commencement and continuation of her employment, dated             , 2001 (the
“Confidentiality Agreement”). 
  
 If Employee is
forty (40) years of age or older as of the Separation Date, Employee acknowledges that she is knowingly and voluntarily waiving and releasing any rights she may have under the federal Age Discrimination in Employment Act of 1967, as amended
(“ADEA”). Employee also acknowledges that the consideration given for the Release above is in addition to anything of value to which she was already entitled. Employee further acknowledges that she has been advised by this writing,
as required by the ADEA and as provided under the Older Workers Benefit Protection Act of 1990, that (a) she has the right to consult with an attorney before signing this Release; (b) her Release does not apply to any rights or claims that may arise
after the date she signs this Release; (c) she has twenty-one (21) days after receipt of notice of her termination and a copy of this Release in final form within which she may review and consider this Release, discuss it with an attorney of her own
choosing, and decide to execute or not execute it (although she may choose to voluntarily execute this Release earlier); (d) she has a period of seven (7) days after she signs this Release to revoke the Release; and (e) this Release will not be
effective (the “Release Effective Date”) until the eighth day after this Release has been signed by Employee, and only then if Employee does not revoke it. In order to revoke this Release, Employee must deliver to the Company,
within seven (7) days after she has signed this Release, a letter stating that she is revoking it. Employee understands that if she chooses to revoke this Release within seven (7) days after she signs it, she will not receive any severance benefits
and the Release will have no effect. 
  
 If Employee is not forty
(40) years of age or older as of the Separation Date, the Release Effective Date will be the date that both parties have signed this Release. 

 Voluntary Execution of Agreement. This Agreement is executed voluntarily and without any duress or
undue influence on the part or behalf of the parties hereto, with the full intent of releasing all claims. The parties acknowledge that: 
  
 (a) They have read this Agreement; 
  
 (b) They have been represented in the preparation, negotiation and execution of this Agreement by legal counsel of their own choice or that they have
voluntarily declined to seek such counsel; 
  
 (c) They understand
the terms and consequences of this Agreement and of the releases it contains; and 
  
 (d) They are fully aware of the legal and binding effect of this Agreement. 
  
 IN WITNESS WHEREOF, the parties have executed this Agreement on the respective dates set forth below. 
  

	JOANNA S.L. BLACK, an individual	 	 	 	XCYTE THERAPIES, INC.
				
	  

	 	 	 	 By:
	 	  

					
	 	 	 	 	 	 	 Its:
	 	  

					
	 Dated:
	 	  

	 	 	 	 Dated:<PAGE>

                                                                   EXHIBIT 10.49

                         COMMON STOCK PURCHASE AGREEMENT

        COMMON STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of October
9, 2003 by and between UNIGENE LABORATORIES, INC., a Delaware corporation (the
"Company"), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability
company (the "Buyer"). Capitalized terms used herein and not otherwise defined
herein are defined in Section 10 hereof.

                                    WHEREAS:

        Subject to the terms and conditions set forth in this Agreement, the
Company wishes to sell to the Buyer, and the Buyer wishes to buy from the
Company, up to Fifteen Million Dollars ($15,000,000) of the Company's common
stock, par value $0.01 per share (the "Common Stock"). The shares of Common
Stock to be purchased hereunder are referred to herein as the "Purchase Shares."

        NOW THEREFORE, the Company and the Buyer hereby agree as follows:

        1.      PURCHASE OF COMMON STOCK.

        Subject to the terms and conditions set forth in Sections 6, 7 and 9
below, the Company hereby agrees to sell to the Buyer, and the Buyer hereby
agrees to purchase from the Company, shares of Common Stock as follows:

        (a)     Commencement of Purchases of Common Stock. The purchase and sale
of Common Stock hereunder shall commence (the "Commencement") within five (5)
Trading Days following the date of satisfaction (or waiver) of the conditions to
the Commencement set forth in Sections 6 and 7 below (or such later date as is
mutually agreed to by the Company and Buyer) (the date of such Commencement, the
"Commencement Date").

        (b)     Buyer's Purchase Rights and Obligations. Subject to the
Company's right to suspend purchases under Section 1(d)(ii) hereof, the Buyer
shall purchase shares of Common Stock on each Trading Day during each Monthly
Period equal to the Daily Purchase Amount (as defined in Section 1(c)(i)) at the
Purchase Price. Within one (1) Trading Day of receipt of Purchase Shares, the
Buyer shall pay to the Company an amount equal to the Purchase Amount with
respect to such Purchase Shares as full payment for the purchase of the Purchase
Shares so received. The Company shall not issue any fraction of a share of
Common Stock upon any purchase. All shares of Common Stock (including fractions
thereof) issuable upon a purchase under this Agreement shall be aggregated for
purposes of determining whether the purchase would result in the issuance of a
fraction of a share of Common Stock. If, after the aforementioned aggregation,
the issuance would result in the issuance of a fraction of a share of Common
Stock, the Company shall round such fraction of a share of Common Stock up or
down to the nearest whole share. All payments made under this Agreement shall be
made in lawful money of the United States of America by wire transfer of
immediately available funds to such account as the Company may from time to time
designate by written notice in accordance with the provisions of this Agreement.
Whenever any amount expressed to be due by the terms of this Agreement is due on
any day that is not a Trading Day, the same shall instead be due on the next
succeeding day which is a Trading Day.

<PAGE>

        (c)     The Daily Purchase Amount; Company's Right to Decrease or
Increase the Daily Purchase Amount.

                (i)     The Daily Purchase Amount. As used herein the term
        "Original Daily Purchase Amount" shall mean Thirty Thousand Dollars
        ($30,000) per Trading Day. As used herein, the term "Daily Purchase
        Amount" shall mean initially Thirty Thousand Dollars ($30,000) per
        Trading Day, which amount may be increased or decreased from time to
        time pursuant to this Section 1(c).

                (ii)    Company's Right to Decrease the Daily Purchase Amount.
        The Company shall always have the right at any time to decrease the
        amount of the Daily Purchase Amount by delivering written notice (a
        "Daily Purchase Amount Decrease Notice") to the Buyer which notice shall
        specify the new Daily Purchase Amount. The decrease in the Daily
        Purchase Amount shall become effective one Trading Day after receipt by
        the Buyer of the Daily Purchase Amount Decrease Notice. Any purchases by
        the Buyer which have a Purchase Date on or prior to the first (1st)
        Trading Day after receipt by the Buyer of a Daily Purchase Amount
        Decrease Notice must be honored by the Company as otherwise provided
        herein. The decrease in the Daily Purchase Amount shall remain in effect
        until the Company delivers to the Buyer a Daily Purchase Amount Increase
        Notice (as defined below).

                (iii)   Company's Right to Increase the Daily Purchase Amount.
        The Company shall have the right (but not the obligation) to increase
        the amount of the Daily Purchase Amount in accordance with the terms and
        conditions set forth in this Section 1(c)(iii) by delivering written
        notice to the Buyer stating the new amount of the Daily Purchase Amount
        (a "Daily Purchase Amount Increase Notice"). A Daily Purchase Amount
        Increase Notice shall be effective five (5) Trading Days after receipt
        by the Buyer. The Company shall always have the right at any time to
        increase the amount of the Daily Purchase Amount up to the Original
        Daily Purchase Amount. With respect to increases in the Daily Purchase
        Amount above the Original Daily Purchase Amount, as the market price for
        the Common Stock increases the Company shall have the right from time to
        time to increase the Daily Purchase Amount as follows. For every $0.10
        increase in Threshold Price above $0.70 (subject to equitable adjustment
        for any reorganization, recapitalization, non-cash dividend, stock split
        or other similar transaction), the Company shall have the right to
        increase the Daily Purchase Amount by up to an additional $7,500 in
        excess of the Original Daily Purchase Amount. "Threshold Price" for
        purposes hereof means the lowest Sale Price of the Common Stock during
        the five (5) consecutive Trading Days immediately prior to the
        submission to the Buyer of a Daily Purchase Amount Increase Notice
        (subject to equitable adjustment for any reorganization,
        recapitalization, non-cash dividend, stock split or other similar
        transaction). For example, if the Threshold Price is $1.00, the Company
        shall have the right to increase the Daily Purchase Amount to up to
        $52,500 in the aggregate. If the Threshold Price is $1.20, the Company
        shall have the right to increase the Daily Purchase Amount to up to
        $67,500 in the aggregate. Any increase in the amount of the Daily
        Purchase Amount shall continue in effect until the delivery to the Buyer
        of a Daily Purchase Amount Decrease Notice. However, if at any time
        during any Trading Day the Sale Price of the Common Stock is below the
        applicable Threshold Price, such increase in the Daily Purchase Amount
        shall be void and the Buyer's obligations to buy Purchase Shares
        hereunder in excess of the applicable maximum Daily Purchase Amount
        shall be terminated. Thereafter, the Company shall again have the right
        to increase the amount of the Daily Purchase Amount as set forth herein
        by delivery of a new Daily Purchase Amount Increase Notice only if the
        Sale Price of the Common Stock is above the applicable Threshold Price
        on each of five (5) consecutive Trading Days immediately prior to such
        new Daily Purchase Amount Increase Notice.

                                        2

<PAGE>

        (d)     Limitations on Purchases.

                (i)     Limitation on Beneficial Ownership. The Company shall
        not effect any sale under this Agreement and the Buyer shall not have
        the right to purchase shares of Common Stock under this Agreement to the
        extent that after giving effect to such purchase the Buyer together with
        its affiliates would beneficially own in excess of 4.9% of the
        outstanding shares of the Common Stock following such purchase. For
        purposes hereof, the number of shares of Common Stock beneficially owned
        by the Buyer and its affiliates or acquired by the Buyer and its
        affiliates, as the case may be, shall include the number of shares of
        Common Stock issuable in connection with a purchase under this Agreement
        with respect to which the determination is being made, but shall exclude
        the number of shares of Common Stock which would be issuable upon (1) a
        purchase of the remaining Available Amount which has not been submitted
        for purchase, and (2) exercise or conversion of the unexercised or
        unconverted portion of any other securities of the Company (including,
        without limitation, any warrants) subject to a limitation on conversion
        or exercise analogous to the limitation contained herein beneficially
        owned by the Buyer and its affiliates. If the 4.9% limitation is ever
        reached the Company shall have the option to increase such limitation to
        9.9% by delivery of written notice to the Buyer. Thereafter, if the 9.9%
        limitation is ever reached this shall not affect or limit the Buyer's
        obligation to purchase the Daily Purchase Amount as otherwise provided
        in this Agreement. Specifically, even though the Buyer may not receive
        additional shares of Common Stock in the event that the 9.9% limitation
        is ever reached, the Buyer is still obligated to pay to the Company the
        Daily Purchase Amount on each Trading Day as otherwise obligated under
        this Agreement, e.g. no Event of Default (as defined in Section 9
        hereof) has occurred, nor any event which, after notice and/or lapse of
        time, would become an Event of Default. Under such circumstances, the
        Buyer would have the right to acquire additional shares of Common Stock
        in the future only at such time as its ownership subsequently become
        less than the 9.9% limitation. For purposes of this Section, in
        determining the number of outstanding shares of Common Stock the Buyer
        may rely on the number of outstanding shares of Common Stock as
        reflected in (1) the Company's most recent Form 10-Q or Form 10-K, as
        the case may be, (2) a more recent public announcement by the Company or
        (3) any other written communication by the Company or its Transfer Agent
        setting forth the number of shares of Common Stock outstanding. Upon the
        reasonable written or oral request of the Buyer, the Company shall
        promptly confirm orally and in writing to the Buyer the number of shares
        of Common Stock then outstanding. In any case, the number of outstanding
        shares of Common Stock shall be determined after giving effect to any
        purchases under this Agreement by the Buyer since the date as of which
        such number of outstanding shares of Common Stock was reported. Except
        as otherwise set forth herein, for purposes of this Section 1(d)(i),
        beneficial ownership shall be determined in accordance with Section
        13(d) of the Securities Exchange Act of 1934, as amended.

                (ii)    Company's Right to Suspend Purchases. The Company may,
        at any time, give written notice (a "Purchase Suspension Notice") to the
        Buyer suspending purchases of Purchase Shares by the Buyer under this
        Agreement. The Purchase Suspension Notice shall be effective only for
        purchases that have a Purchase Date later than one (1) Trading Day after
        receipt of the Purchase Suspension Notice by the Buyer. Any purchase by
        the Buyer that has a Purchase Date on or prior to the first (1st)
        Trading Day after receipt by the Buyer of a Purchase Suspension Notice
        from the Company must be honored by the Company as otherwise provided
        herein. Such purchase suspension shall continue in effect until a
        revocation in writing by the Company, at its sole discretion. So long as
        a Purchase Suspension Notice is in effect, the Buyer shall not be
        obligated to purchase any Purchase Shares from the Company under Section
        1 of this Agreement.

                                        3

<PAGE>

                (iii)   Purchase Price Floor. The Company shall not affect any
        sales under this Agreement and the Buyer shall not have the right nor
        the obligation to purchase any Purchase Shares under this Agreement on
        any Trading Day where the Purchase Price for any purchases of Purchase
        Shares would be less than the Floor Price.

        (e)     Records of Purchases. The Buyer and the Company shall each
maintain records showing the remaining Available Amount at any give time and the
dates and Purchase Amounts for each purchase or shall use such other method,
reasonably satisfactory to the Buyer and the Company.

        (f)     Taxes. The Company shall pay any and all transfer, stamp or
similar taxes that may be payable with respect to the issuance and delivery of
any shares of Common Stock to the Buyer made under this Agreement.

        2.      BUYER'S REPRESENTATIONS AND WARRANTIES.

        The Buyer represents and warrants to the Company that as of the date
hereof and as of the Commencement Date:

        (a)     Investment Purpose. The Buyer is entering into this Agreement
and acquiring the Commitment Shares, Warrants and Warrant Shares (as defined in
Section 4(f) hereof) (this Agreement and the Commitment Shares, Warrants and
Warrant Shares are collectively referred to herein as the "Securities"), for its
own account for investment only and not with a view towards, or for resale in
connection with, the public sale or distribution thereof; provided however, by
making the representations herein, the Buyer does not agree to hold any of the
Securities for any minimum or other specific term.

        (b)     Accredited Investor Status. The Buyer is an "accredited
investor" as that term is defined in Rule 501(a)(3) of Regulation D.

        (c)     Reliance on Exemptions. The Buyer understands that the
Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities
laws and that the Company is relying in part upon the truth and accuracy of, and
the Buyer's compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Buyer set forth herein in order to
determine the availability of such exemptions and the eligibility of the Buyer
to acquire the Securities.

        (d)     Information. The Buyer has been furnished with all materials
relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities that have been reasonably
requested by the Buyer, including, without limitation, the SEC Documents (as
defined in Section 3(f) hereof). The Buyer understands that its investment in
the Securities involves a high degree of risk. The Buyer (i) is able to bear the
economic risk of an investment in the Securities including a total loss, (ii)
has such knowledge and experience in financial and business matters that it is
capable of evaluating the merits and risks of the proposed investment in the
Securities and (iii) has had an opportunity to ask questions of and receive
answers from the officers of the Company concerning the financial condition and
business of the Company and others matters related to an investment in the
Securities. Neither such inquiries nor any other due diligence investigations
conducted by the Buyer or its representatives shall modify, amend or affect the
Buyer's right to rely on the Company's representations and warranties contained
in Section 3 below. The Buyer has sought such accounting, legal and tax advice
as it has considered necessary to make an informed investment decision with
respect to its acquisition of the Securities.

                                        4

<PAGE>

        (e)     No Governmental Review. The Buyer understands that no United
States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the
fairness or suitability of the investment in the Securities nor have such
authorities passed upon or endorsed the merits of the offering of the
Securities.

        (f)     Transfer or Resale. The Buyer understands that except as
provided in the Registration Rights Agreement (as defined in Section 4(a)
hereof): (i) the Securities have not been and are not being registered under the
1933 Act or any state securities laws, and may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder or (B) an
exemption exists permitting such Securities to be sold, assigned or transferred
without such registration; (ii) any sale of the Securities made in reliance on
Rule 144 may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed
to be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and
regulations of the SEC thereunder; and (iii) neither the Company nor any other
person is under any obligation to register the Securities under the 1933 Act or
any state securities laws or to comply with the terms and conditions of any
exemption thereunder.

        (g)     Validity; Enforcement. This Agreement has been duly and validly
authorized, executed and delivered on behalf of the Buyer and is a valid and
binding agreement of the Buyer enforceable against the Buyer in accordance with
its terms, subject as to enforceability to general principles of equity and to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and
other similar laws relating to, or affecting generally, the enforcement of
applicable creditors' rights and remedies.

        (h)     Residency. The Buyer is a resident of the State of Illinois.

        (i)     No Prior Short Selling. The Buyer represents and warrants to the
Company that at no time prior to the date of this Agreement has any of the
Buyer, its agents, representatives or affiliates engaged in or effected, in any
manner whatsoever, directly or indirectly, any (i) "short sale" (as such term is
defined in Rule 3b-3 of the 1934 Act) of the Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Common
Stock.

        3.      REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

        The Company represents and warrants to the Buyer that as of the date
hereof and as of the Commencement Date:

        (a)     Organization and Qualification. The Company and its
"Subsidiaries" (which for purposes of this Agreement means any entity in which
the Company, directly or indirectly, owns 50% or more of the voting stock or
capital stock or other similar equity interests) are corporations duly organized
and validly existing in good standing under the laws of the jurisdiction in
which they are incorporated, and have the requisite corporate power and
authority to own their properties and to carry on their business as now being
conducted. Each of the Company and its Subsidiaries is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it
makes such qualification necessary, except to the extent that the failure to be
so qualified or be in good standing could not reasonably be expected to have a
Material Adverse Effect. As used in this Agreement, "Material Adverse Effect"
means any material adverse effect on any of: (i) the business, properties,
assets, operations, results of operations or financial condition of the Company
and its Subsidiaries, if any, taken as a whole, or (ii) the authority or ability
of the Company to

                                        5

<PAGE>

perform its obligations under the Transaction Documents (as defined in Section
3(b) hereof). The Company has no Subsidiaries except as set forth on Schedule
3(a).

        (b)     Authorization; Enforcement; Validity. (i) The Company has the
requisite corporate power and authority to enter into and perform its
obligations under this Agreement, the Registration Rights Agreement and each of
the other agreements entered into by the parties on the Commencement Date and
attached hereto as exhibits to this Agreement (collectively, the "Transaction
Documents"), and to issue the Securities in accordance with the terms hereof and
thereof, (ii) the execution and delivery of the Transaction Documents by the
Company and the consummation by it of the transactions contemplated hereby and
thereby, including without limitation, the issuance of the Commitment Shares and
the reservation for issuance and the issuance of the Purchase Shares issuable
under this Agreement, have been duly authorized by the Company's Board of
Directors and no further consent or authorization is required by the Company,
its Board of Directors or its shareholders, (iii) this Agreement has been, and
each other Transaction Document shall be on the Commencement Date, duly executed
and delivered by the Company and (iv) this Agreement constitutes, and each other
Transaction Document upon its execution on behalf of the Company, shall
constitute, the valid and binding obligations of the Company enforceable against
the Company in accordance with their terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally, the enforcement of creditors' rights and remedies. The
Board of Directors of the Company has approved the resolutions (the "Signing
Resolutions") substantially in the form as set forth as Exhibit C-1 attached
hereto to authorize this Agreement and the transactions contemplated hereby. The
Signing Resolutions are valid, in full forth and effect and have not been
modified or supplemented in any respect other than by the resolutions set forth
in Exhibit C-2 attached hereto regarding the registration statement referred to
in Section 4 hereof. The Company has delivered to the Buyer a true and correct
copy of a unanimous written consent adopting the Signing Resolutions executed by
all of the members of the Board of Directors of the Company. No other approvals
or consents of the Company's Board of Directors and/or shareholders is necessary
under applicable laws and the Company's Certificate of Incorporation and/or
Bylaws to authorize the execution and delivery of this Agreement or any of the
transactions contemplated hereby, including, but not limited to, the issuance of
the Commitment Shares and the issuance of the Purchase Shares.

        (c)     Capitalization. As of September 30, 2003, the authorized capital
stock of the Company consists of (i) 100,000,000 shares of Common Stock, of
which as of the date hereof, 67,452,185 shares are issued and outstanding, 7,290
are held as treasury shares, 4,602,140 shares are reserved for issuance pursuant
to the Company's stock option plans of which only approximately 1,506,000 shares
remain available for future grants and 1,723,002 shares are issuable and
reserved for issuance pursuant to securities (other than stock options issued
pursuant to the Company's stock option plans) exercisable or exchangeable for,
or convertible into, shares of Common Stock and (ii) no shares of Preferred
Stock are issued and outstanding. All of such outstanding shares have been, or
upon issuance will be, validly issued and are fully paid and nonassessable.
Except as disclosed in Schedule 3(c), (i) no shares of the Company's capital
stock are subject to preemptive rights or any other similar rights or any liens
or encumbrances suffered or permitted by the Company, (ii) there are no
outstanding debt securities, (iii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of capital
stock of the Company or any of its Subsidiaries, or contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to issue additional shares of capital stock of the
Company or any of its Subsidiaries or options, warrants, scrip, rights to
subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, any shares of capital stock of the
Company or any of its Subsidiaries, (iv) there are no agreements or arrangements
under which the Company or any of its Subsidiaries is obligated to register the
sale of any of their securities under the 1933 Act (except the Registration
Rights Agreement), (v) there are no outstanding

                                        6

<PAGE>

securities or instruments of the Company or any of its Subsidiaries which
contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries, (vi) there are no securities or instruments containing
anti-dilution or similar provisions that will be triggered by the issuance of
the Securities as described in this Agreement and (vii) the Company does not
have any stock appreciation rights or "phantom stock" plans or agreements or any
similar plan or agreement. The Company has furnished to the Buyer true and
correct copies of the Company's Certificate of Incorporation, as amended and as
in effect on the date hereof (the "Certificate of Incorporation"), and the
Company's By-laws, as amended and as in effect on the date hereof (the
"By-laws"), and summaries of the terms of all securities convertible into or
exercisable for Common Stock, if any, and copies of any documents containing the
material rights of the holders thereof in respect thereto.

        (d)     Issuance of Securities. The Commitment Shares and Warrants have
been duly authorized and, upon issuance in accordance with the terms hereof, the
Commitment Shares shall be (i) validly issued, fully paid and non-assessable and
(ii) free from all taxes, liens and charges with respect to the issue thereof.
8,500,000 shares of Common Stock have been duly authorized and reserved for
issuance upon purchase under this Agreement. Upon issuance and payment therefor
in accordance with the terms and conditions of this Agreement and the Warrants,
the Purchase Shares and Warrant Shares, respectively, shall be validly issued,
fully paid and nonassessable and free from all taxes, liens and charges with
respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock.

        (e)     No Conflicts. Except as disclosed in Schedule 3(e), the
execution, delivery and performance of the Transaction Documents by the Company
and the consummation by the Company of the transactions contemplated hereby and
thereby (including, without limitation, the reservation for issuance and
issuance of the Purchase Shares) will not (i) result in a violation of the
Certificate of Incorporation, any Certificate of Designations, Preferences and
Rights of any outstanding series of preferred stock of the Company or the
By-laws or (ii) conflict with, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Company or any of its
Subsidiaries is a party, or result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws and
regulations and the rules and regulations of the Principal Market applicable to
the Company or any of its Subsidiaries) or by which any property or asset of the
Company or any of its Subsidiaries is bound or affected, except in the case of
conflicts, defaults and violations under clause (ii), which could not reasonably
be expected to result in a Material Adverse Effect. Except as disclosed in
Schedule 3(e), neither the Company nor its Subsidiaries is in violation of any
term of or in default under its Certificate of Incorporation, any Certificate of
Designation, Preferences and Rights of any outstanding series of preferred stock
of the Company or By-laws or their organizational charter or by-laws,
respectively. Except as disclosed in Schedule 3(e), neither the Company nor any
of its Subsidiaries is in violation of any term of or is in default under any
material contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order or any statute, rule or regulation applicable to the
Company or its Subsidiaries, except for possible conflicts, defaults,
terminations or amendments which could not reasonably be expected to have a
Material Adverse Effect. The business of the Company and its Subsidiaries is not
being conducted, and shall not be conducted, in violation of any law, ordinance,
regulation of any governmental entity, except for possible violations, the
sanctions for which either individually or in the aggregate could not reasonably
be expected to have a Material Adverse Effect. Except as specifically
contemplated by this Agreement and as required under the 1933 Act or applicable
state securities laws, the Company is not required to obtain any consent,
authorization or order of, or make any filing or registration with, any court or
governmental agency or any regulatory or self-regulatory agency in order for it
to execute, deliver or perform any of its obligations under or contemplated by
the Transaction Documents in accordance with the terms hereof or

                                        7

<PAGE>

thereof. Except as disclosed in Schedule 3(e), all consents, authorizations,
orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence shall be obtained or effected on or prior to
the Commencement Date. Except as listed in Schedule 3(e), since August 31, 2002,
the Company has not received nor delivered any notices or correspondence from or
to the Principal Market. The Principal Market has not commenced any delisting
proceedings against the Company.

        (f)     SEC Documents; Financial Statements. Except as disclosed in
Schedule 3(f), since January 1, 2002, the Company has timely filed all reports,
schedules, forms, statements and other documents required to be filed by it with
the SEC pursuant to the reporting requirements of the Securities Exchange Act of
1934, as amended (the "1934 Act") (all of the foregoing filed prior to the date
hereof and all exhibits included therein and financial statements and schedules
thereto and documents incorporated by reference therein being hereinafter
referred to as the "SEC Documents"). As of their respective dates (except as
they have been correctly amended), the SEC Documents complied in all material
respects with the requirements of the 1934 Act and the rules and regulations of
the SEC promulgated thereunder applicable to the SEC Documents, and none of the
SEC Documents, at the time they were filed with the SEC (except as they may have
been properly amended), contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. As of their respective dates (except as they
have been properly amended), the financial statements of the Company included in
the SEC Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with
respect thereto. Such financial statements have been prepared in accordance with
generally accepted accounting principles, consistently applied, during the
periods involved (except (i) as may be otherwise indicated in such financial
statements or the notes thereto or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments). Except as listed in
Schedule 3(f), the Company has received no notices or correspondence from the
SEC since August 31, 2002. The SEC has not commenced any enforcement proceedings
against the Company or any of its subsidiaries.

        (g)     Absence of Certain Changes. Except as disclosed in Schedule
3(g), since July 1, 2003, there has been no material adverse change in the
business, properties, operations, financial condition or results of operations
of the Company or its Subsidiaries. The Company has not taken any steps, and
does not currently expect to take any steps, to seek protection pursuant to any
Bankruptcy Law nor does the Company or any of its Subsidiaries have any
knowledge or reason to believe that its creditors intend to initiate involuntary
bankruptcy or insolvency proceedings.

        (h)     Absence of Litigation. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the
Company or any of its Subsidiaries, threatened against or affecting the Company,
the Common Stock or any of the Company's Subsidiaries or any of the Company's or
the Company's Subsidiaries' officers or directors in their capacities as such,
which could reasonably be expected to have a Material Adverse Effect. A
description of each action, suit, proceeding, inquiry or investigation before or
by any court, public board, government agency, self-regulatory organization or
body which, as of the date of this Agreement, is pending or threatened in
writing against or affecting the Company, the Common Stock or any of the
Company's Subsidiaries or any of the Company's or the Company's Subsidiaries'
officers or directors in their capacities as such, is set forth in Schedule
3(h).

        (i)     Acknowledgment Regarding Buyer's Status. The Company
acknowledges and agrees that the Buyer is acting solely in the capacity of arm's
length purchaser with respect to the Transaction

                                        8

<PAGE>

Documents and the transactions contemplated hereby and thereby. The Company
further acknowledges that the Buyer is not acting as a financial advisor or
fiduciary of the Company (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated hereby and thereby and
any advice given by the Buyer or any of its representatives or agents in
connection with the Transaction Documents and the transactions contemplated
hereby and thereby is merely incidental to the Buyer's purchase of the
Securities. The Company further represents to the Buyer that the Company's
decision to enter into the Transaction Documents has been based solely on the
independent evaluation by the Company and its representatives and advisors.

        (j)     No General Solicitation. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has engaged in any
form of general solicitation or general advertising (within the meaning of
Regulation D under the 1933 Act) in connection with the offer or sale of the
Securities.

        (k)     Dilutive Effect. The Company understands and acknowledges that
the number of Purchase Shares purchasable under this Agreement is not fixed and
will vary depending on the Purchase Price at which such shares are purchased.
The Company further acknowledges that its obligation to issue Purchase Shares
under this Agreement in accordance with the terms and conditions hereof is
absolute and unconditional regardless of the dilutive effect that such issuance
may have on the ownership interests of other shareholders of the Company.

        (l)     Intellectual Property Rights. The Company and its Subsidiaries
own or possess adequate rights or licenses to use all material trademarks, trade
names, service marks, service mark registrations, service names, patents, patent
rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets and rights necessary to conduct their respective
businesses as now conducted. Except as set forth on Schedule 3(l), none of the
Company's material trademarks, trade names, service marks, service mark
registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, government authorizations, trade secrets or other
intellectual property rights have expired or terminated, or, by the terms and
conditions thereof, are scheduled to expire or terminate within two years from
the date of this Agreement. The Company and its Subsidiaries do not have any
knowledge of any infringement by the Company or its Subsidiaries of any material
trademark, trade name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations, trade secret
or other similar rights of others, or of any such development of similar or
identical trade secrets or technical information by others and, except as set
forth on Schedule 3(l), there is no claim, action or proceeding being made or
brought against, or to the Company's knowledge, being threatened against, the
Company or its Subsidiaries regarding trademark, trade name, patents, patent
rights, invention, copyright, license, service names, service marks, service
mark registrations, trade secret or other infringement, which could reasonably
be expected to have a Material Adverse Effect.

        (m)     Environmental Laws. The Company and its Subsidiaries (i) are in
compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or
contaminants ("Environmental Laws"), (ii) have received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct
their respective businesses and (iii) are in compliance with all terms and
conditions of any such permit, license or approval, except where, in each of the
three foregoing clauses, the failure to so comply could not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.

        (n)     Title. The Company and its Subsidiaries have good and marketable
title in fee simple to all real property and good and marketable title to all
personal property owned by them which is material to the business of the Company
and its Subsidiaries, in each case free and clear of all liens, encumbrances and
defects except such as are described in Schedule 3(n) or such as do not
materially affect the value of

                                        9

<PAGE>

such property and do not interfere with the use made and proposed to be made of
such property by the Company and any of its Subsidiaries. Any real property and
facilities held under lease by the Company and any of its Subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as
are not material and do not interfere with the use made and proposed to be made
of such property and buildings by the Company and its Subsidiaries.

        (o)     Insurance. The Company and each of its Subsidiaries are insured
by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and
customary in the businesses in which the Company and its Subsidiaries are
engaged. Neither the Company nor any such Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business at a cost that would not materially and
adversely affect the condition, financial or otherwise, or the earnings,
business or operations of the Company and its Subsidiaries, taken as a whole.

        (p)     Regulatory Permits. The Company and its Subsidiaries possess all
material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their
respective businesses, and neither the Company nor any such Subsidiary has
received any notice of proceedings relating to the revocation or modification of
any such certificate, authorization or permit.

        (q)     Tax Status. The Company and each of its Subsidiaries has made or
filed all federal and state income and all other material tax returns, reports
and declarations required by any jurisdiction to which it is subject (unless and
only to the extent that the Company and each of its Subsidiaries has set aside
on its books provisions reasonably adequate for the payment of all unpaid and
unreported taxes) and has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith
and has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports
or declarations apply. There are no unpaid taxes in any material amount claimed
to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.

        (r)     Transactions With Affiliates. Except as set forth on Schedule
3(r) and other than the grant or exercise of stock options disclosed on Schedule
3(c), none of the officers, directors, or employees of the Company is presently
a party to any transaction with the Company or any of its Subsidiaries (other
than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has an interest or is an
officer, director, trustee or partner.

        (s)     Application of Takeover Protections. The Company and its board
of directors have taken or will take prior to the Commencement Date all
necessary action, if any, in order to render inapplicable any control share
acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the
Certificate of Incorporation or the laws of the state of its incorporation which
is or could become applicable to the Buyer as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company's
issuance of the Securities and the Buyer's ownership of the Securities.

        (t)     Foreign Corrupt Practices. Neither the Company, nor any of its
Subsidiaries, nor any director, officer, agent, employee or other person acting
on behalf of the Company or any of its

                                       10

<PAGE>

Subsidiaries has, in the course of its actions for, or on behalf of, the
Company, used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; made
any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; violated or is in violation of any
provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or made
any unlawful bribe, rebate, payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.

        4.      COVENANTS.

        (a)     Filing of Registration Statement. The Company shall within
thirty (30) Trading Days from the date hereof file a new registration statement
covering the sale of the Commitment Shares, Warrant Shares and at least
8,500,000 Purchase Shares in accordance with the terms of the Registration
Rights Agreement between the Company and the Buyer, dated as of the date hereof
("Registration Rights Agreement.").

        (b)     Blue Sky. The Company shall take such action, if any, as is
reasonably necessary in order to obtain an exemption for or to qualify (i) the
initial sale of the Commitment Shares and any Purchase Shares to the Buyer under
this Agreement and (ii) any subsequent resale of the Commitment Shares and any
Purchase Shares by the Buyer, in each case, under applicable securities or "Blue
Sky" laws of the states of the United States in such states as is reasonably
requested by the Buyer from time to time, and shall provide evidence of any such
action so taken to the Buyer.

        (c)     [Intentionally Omitted.]

        (d)     Listing. The Company shall promptly secure the listing of all of
the Purchase Shares and Commitment Shares upon each national securities exchange
and automated quotation system, if any, upon which shares of Common Stock are
then listed (subject to official notice of issuance) and shall maintain, so long
as any other shares of Common Stock shall be so listed, such listing of all such
securities from time to time issuable under the terms of the Transaction
Documents. The Company shall maintain the Common Stock's authorization for
quotation on the Principal Market. Neither the Company nor any of its
Subsidiaries shall take any action that would be reasonably expected to result
in the delisting or suspension of the Common Stock on the Principal Market. The
Company shall promptly, and in no event later than the following Trading Day,
provide to the Buyer copies of any notices it receives from the Principal Market
regarding the continued eligibility of the Common Stock for listing on such
automated quotation system or securities exchange. The Company shall pay all
fees and expenses in connection with satisfying its obligations under this
Section.

        (e)     Limitation on Short Sales and Hedging Transactions. The Buyer
agrees that beginning on the date of this Agreement and ending on the date of
termination of this Agreement as provided in Section 11(k), the Buyer and its
agents, representatives and affiliates shall not in any manner whatsoever enter
into or effect, directly or indirectly, any (i) "short sale" (as such term is
defined in Rule 3b-3 of the 1934 Act) of the Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Common
Stock.

        (f)     Issuance of Commitment Shares and Warrants; Limitation on Sales
of Commitment Shares and Warrant Shares. Immediately upon the execution of this
Agreement, the Company shall issue to the Buyer 1,000,000 shares of Common Stock
(the "Commitment Shares") and warrants (the "Warrants") to purchase 500,000
shares of Common Stock (the "Warrant Shares") in the form of Exhibit F hereto.
The Warrants shall have an exercise price of $0.90 per share and shall be
exercisable for five

                                       11

<PAGE>

(5) years from the date of issuance. The Commitment Shares shall be issued in
certificated form and (subject to Section 5 hereof) shall bear the following
restrictive legend:

        THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
        REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
        APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN
        ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
        TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
        REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
        ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS,
        OR AN OPINION OF BUYER'S COUNSEL, IN A CUSTOMARY FORM, THAT
        REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE
        STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144
        UNDER SAID ACT.

The Buyer agrees that the Buyer shall not transfer or sell the Commitment Shares
or the Warrant Shares until the earlier of 500 Trading Days (25 Monthly Periods)
from the date hereof or the date on which this Agreement has been terminated,
provided, however, that such restrictions shall not apply: (i) in connection
with any transfers to or among affiliates (as defined in the 1934 Act), (ii) in
connection with any pledge in connection with a bona fide loan or margin
account, (iii) in the event that the Commencement does not occur on or before
January 30, 2004, due to the failure of the Company to satisfy the conditions
set forth in Section 7 or (iv) if an Event of Default has occurred, or any event
which, after notice and/or lapse of time, would become an Event of Default,
including any failure by the Company to timely issue Purchase Shares under this
Agreement. Notwithstanding the forgoing, the Buyer may transfer Commitment
Shares or the Warrant Shares to a third party in order to settle a sale made by
the Buyer where the Buyer reasonably expects the Company to deliver Purchase
Shares to the Buyer under this Agreement so long as the Buyer maintains
ownership of the same overall number of shares of Common Stock by "replacing"
the Commitment Shares or the Warrant Shares so transferred with Purchase Shares
when the Purchase Shares are actually issued by the Company to the Buyer.

        (g)     Due Diligence. The Buyer shall have the right, from time to time
as the Buyer may reasonably deem appropriate, to perform reasonable due
diligence on the Company during normal business hours. The Company and its
officers and employees shall provide information and reasonably cooperate with
the Buyer in connection with any reasonable request by the Buyer related to the
Buyer's due diligence of the Company, including, but not limited to, any such
request made by the Buyer in connection with (i) the filing of the registration
statement described in Section 4(a) hereof and (ii) the Commencement.

        5.      TRANSFER AGENT INSTRUCTIONS.

        Immediately upon the execution of this Agreement, the Company shall
deliver to the Transfer Agent a letter in the form as set forth as Exhibit E
attached hereto with respect to the issuance of the Commitment Shares. On the
Commencement Date, the Company shall cause any restrictive legend on the
Commitment Shares and Warrant Shares, if any, to be removed and all of the
Purchase Shares and Warrant Shares to be issued under this Agreement shall be
issued without any restrictive legend. The Company shall issue irrevocable
instructions to the Transfer Agent, and any subsequent transfer agent, to issue
Purchase Shares in the name of the Buyer for the Purchase Shares (the
"Irrevocable Transfer Agent Instructions"). The Company warrants to the Buyer
that no instruction other than the Irrevocable Transfer Agent Instructions
referred to in this Section 5, will be given by the Company to the Transfer
Agent with respect to the Purchase Shares and that the Commitment Shares,
Warrant Shares and the Purchase Shares

                                       12

<PAGE>

shall otherwise be freely transferable on the books and records of the Company
as and to the extent provided in this Agreement and the Registration Rights
Agreement subject to the provisions of Section 4(f) in the case of the
Commitment Shares.

        6.      CONDITIONS TO THE COMPANY'S OBLIGATION TO COMMENCE SALES OF
                SHARES OF COMMON STOCK.

        The obligation of the Company hereunder to commence sales of the
Purchase Shares is subject to the satisfaction of each of the following
conditions on or before the Commencement Date (the date that sales begin) and
once such conditions have been initially satisfied, there shall not be any
ongoing obligation to satisfy such conditions after the Commencement has
occurred; provided that these conditions are for the Company's sole benefit and
may be waived by the Company at any time in its sole discretion by providing the
Buyer with prior written notice thereof:

        (a)     The Buyer shall have executed each of the Transaction Documents
and delivered the same to the Company.

        (b)     Subject to the Company's compliance with Section 4(a), a
registration statement covering the sale of all of the Commitment Shares,
Warrant Shares and at least 8,500,000 Purchase Shares shall have been declared
effective under the 1933 Act by the SEC and no stop order with respect to the
Registration Statement shall be pending or threatened by the SEC.

        (c)     The representations and warranties of the Buyer shall be true
and correct in all material respects as of the date when made and as of the
Commencement Date as though made at that time (except for representations and
warranties that speak as of a specific date), and the Buyer shall have
performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied
or complied with by the Buyer at or prior to the Commencement Date.

        7.      CONDITIONS TO THE BUYER'S OBLIGATION TO COMMENCE PURCHASES OF
                SHARES OF COMMON STOCK.

        The obligation of the Buyer to commence purchases of Purchase Shares
under this Agreement is subject to the satisfaction of each of the following
conditions on or before the Commencement Date (the date that sales begin) and
once such conditions have been initially satisfied, there shall not be any
ongoing obligation to satisfy such conditions after the Commencement has
occurred; provided that these conditions are for the Buyer's sole benefit and
may be waived by the Buyer at any time in its sole discretion by providing the
Company with prior written notice thereof:

        (a)     The Company shall have executed each of the Transaction
Documents and delivered the same to the Buyer.

        (b)     The Company shall have issued to the Buyer the Commitment Shares
and Warrants and shall have removed the restrictive transfer legend from the
certificate representing the Commitment Shares and Warrant Shares, if any.

        (c)     The Common Stock shall be authorized for quotation on the
Principal Market, trading in the Common Stock shall not have been within the
last 365 days suspended by the SEC or the Principal

                                       13

<PAGE>

Market and the Purchase Shares and the Commitment Shares shall be approved for
listing upon the Principal Market.

        (d)     The Buyer shall have received the opinions of the Company's
legal counsel dated as of the Commencement Date substantially in the form of
Exhibit A attached hereto.

        (e)     The representations and warranties of the Company shall be true
and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section
3 above, in which case, such representations and warranties shall be true and
correct without further qualification) as of the date when made and as of the
Commencement Date as though made at that time (except for representations and
warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied with the covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied
with by the Company at or prior to the Commencement Date. The Buyer shall have
received a certificate, executed by the CEO, President or CFO of the Company,
dated as of the Commencement Date, to the foregoing effect in the form attached
hereto as Exhibit B.

        (f)     The Board of Directors of the Company shall have adopted
resolutions in the form attached hereto as Exhibit C which shall be in full
force and effect without any amendment or supplement thereto as of the
Commencement Date.

        (g)     As of the Commencement Date, the Company shall have reserved out
of its authorized and unissued Common Stock, (A) solely for the purpose of
effecting purchases of Purchase Shares hereunder, at least 8,500,000 shares of
Common Stock and (B) as Warrant Shares in accordance with Section 4(f) hereof,
500,000 shares of Common Stock.

        (h)     The Irrevocable Transfer Agent Instructions, in form acceptable
to the Buyer shall have been delivered to and acknowledged in writing by the
Company and the Company's Transfer Agent.

        (i)     The Company shall have delivered to the Buyer a certificate
evidencing the incorporation and good standing of the Company in the State of
Delaware issued by the Secretary of State of the State of Delaware as of a date
within ten (10) Trading Days of the Commencement Date.

        (j)     The Company shall have delivered to the Buyer a certified copy
of the Certificate of Incorporation as certified by the Secretary of State of
the State of Delaware within ten (10) Trading Days of the Commencement Date.

        (k)     The Company shall have delivered to the Buyer a secretary's
certificate executed by the Secretary of the Company, dated as of the
Commencement Date, in the form attached hereto as Exhibit D.

        (l)     A registration statement covering the sale of all of the
Commitment Shares, Warrant Shares and at least 8,500,000 Purchase Shares shall
have been declared effective under the 1933 Act by the SEC and no stop order
with respect to the registration statement shall be pending or threatened by the
SEC. The Company shall have prepared and delivered to the Buyer a final form of
prospectus to be used by the Buyer in connection with any sales of any
Commitment Shares, Warrant Shares or any Purchase Shares. The Company shall have
made all filings under all applicable federal and state securities laws
necessary to consummate the issuance of the Commitment Shares, Warrant Shares
and the Purchase Shares pursuant to this Agreement in compliance with such laws.

                                       14

<PAGE>

        (m)     No Event of Default has occurred, or any event which, after
notice and/or lapse of time, would become an Event of Default has occurred.

        (n)     On or prior to the Commencement Date, the Company shall take all
necessary action, if any, and such actions as reasonably requested by the Buyer,
in order to render inapplicable any control share acquisition, business
combination, shareholder rights plan or poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the
Certificate of Incorporation or the laws of the state of its incorporation which
is or could become applicable to the Buyer as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company's
issuance of the Securities and the Buyer's ownership of the Securities.

        (o)     The Company shall have provided the Buyer with the information
requested by the Buyer in connection with its reasonable due diligence requests
made prior to, or in connection with, the Commencement, in accordance with the
terms of Section 4(g) hereof.

        8.      INDEMNIFICATION.

        In consideration of the Buyer's execution and delivery of the
Transaction Documents and acquiring the Securities hereunder and in addition to
all of the Company's other obligations under the Transaction Documents, the
Company shall defend, protect, indemnify and hold harmless the Buyer and all of
its affiliates, shareholders, officers, directors, employees and direct or
indirect investors and any of the foregoing person's agents or other
representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement) (collectively, the
"Indemnitees") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including
reasonable attorneys' fees and disbursements (the "Indemnified Liabilities"),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the
Company in the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of the Company contained in the Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby, or
(c) any cause of action, suit or claim brought or made against such Indemnitee
and arising out of or resulting from the execution, delivery, performance or
enforcement of the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, other than with respect to Indemnified
Liabilities which directly and primarily result from the gross negligence or
willful misconduct of the Indemnitee. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of
the Indemnified Liabilities which is permissible under applicable law.

        9.      EVENTS OF DEFAULT.

        An "Event of Default" shall be deemed to have occurred at any time as
any of the following events occurs:

        (a)     while any registration statement is required to be maintained
effective pursuant to the terms of the Registration Rights Agreement, the
effectiveness of such registration statement lapses for any reason (including,
without limitation, the issuance of a stop order) or is unavailable to the Buyer
for sale of all of the Registrable Securities (as defined in the Registration
Rights Agreement) in accordance with the terms of the Registration Rights
Agreement, and such lapse or unavailability continues for a period of

                                       15

<PAGE>

ten (10) consecutive Trading Days or for more than an aggregate of thirty (30)
Trading Days in any 365-day period;

        (b)     the suspension from trading or failure of the Common Stock to be
listed on the Principal Market for a period of three (3) consecutive Trading
Days;

        (c)     the delisting of the Company's Common Stock from the Principal
Market, provided, however, that the Common Stock is not immediately thereafter
trading on the New York Stock Exchange, the Nasdaq National Market, the Nasdaq
SmallCap Market, or the American Stock Exchange;

        (d)     the failure for any reason by the Transfer Agent to issue
Purchase Shares to the Buyer within five (5) Trading Days after the applicable
Purchase Date which the Buyer is entitled to receive;

        (e)     the Company breaches any representation, warranty, covenant or
other term or condition under any Transaction Document if such breach could
reasonably be expected to have a Material Adverse Effect and except, in the case
of a breach of a covenant which is reasonably curable, only if such breach
continues for a period of at least ten (10) Trading Days;

        (f)     except as set forth on Schedule 9(f), any payment default under
any contract whatsoever or any acceleration prior to maturity of any mortgage,
indenture, contract or instrument under which there may be issued or by which
there may be secured or evidenced any indebtedness for money borrowed by the
Company or for money borrowed the repayment of which is guaranteed by the
Company, whether such indebtedness or guarantee now exists or shall be created
hereafter, which, with respect to any such payment default or acceleration prior
to maturity, is in excess of $1,000,000;

        (g)     if any Person commences a proceeding against the Company
pursuant to or within the meaning of any Bankruptcy Law;

        (h)     if the Company pursuant to or within the meaning of any
Bankruptcy Law; (A) commences a voluntary case, (B) consents to the entry of an
order for relief against it in an involuntary case, (C) consents to the
appointment of a Custodian of it or for all or substantially all of its
property, (D) makes a general assignment for the benefit of its creditors, (E)
becomes insolvent, or (F) is generally unable to pay its debts as the same
become due; or

        (i)     a court of competent jurisdiction enters an order or decree
under any Bankruptcy Law that (A) is for relief against the Company in an
involuntary case, (B) appoints a Custodian of the Company or for all or
substantially all of its property, or (C) orders the liquidation of the Company
or any Subsidiary.

In addition to any other rights and remedies under applicable law and this
Agreement, including the Buyer termination rights under Section 11(k) hereof, so
long as an Event of Default has occurred and is continuing, or if any event
which, after notice and/or lapse of time, would become an Event of Default, has
occurred and is continuing, or so long as the Purchase Price is below the
Purchase Price Floor, the Buyer shall not be obligated to purchase any shares of
Common Stock under this Agreement. If pursuant to or within the meaning of any
Bankruptcy Law, the Company commences a voluntary case or any Person commences a
proceeding against the Company, a Custodian is appointed for the Company or for
all or substantially all of its property, or the Company makes a general
assignment for the benefit of its creditors, (any of which would be an Event of
Default as described in Sections 9(g), 9(h) and 9(i) hereof) this Agreement
shall automatically terminate without any liability or payment to the Company
without further action or notice by any Person. No such termination of this
Agreement under Section 11(k)(i) shall affect the Company's or the Buyer's
obligations under this Agreement with respect to pending

                                       16

<PAGE>

purchases and the Company and the Buyer shall complete their respective
obligations with respect to any pending purchases under this Agreement.

        10.     CERTAIN DEFINED TERMS.

        For purposes of this Agreement, the following terms shall have the
following meanings:

        (a)     "1933 Act" means the Securities Act of 1933, as amended.

        (b)     "Available Amount" means initially Fifteen Million Dollars
($15,000,000) in the aggregate which amount shall be reduced by the Purchase
Amount each time the Buyer purchases shares of Common Stock pursuant to Section
1 hereof.

        (c)     "Bankruptcy Law" means Title 11, U.S. Code, or any similar
federal or state law for the relief of debtors.

        (d)     "Closing Sale Price" means, for any security as of any date, the
last closing trade price for such security on the Principal Market as reported
by Bloomberg, or, if the Principal Market is not the principal securities
exchange or trading market for such security, the last closing trade price of
such security on the principal securities exchange or trading market where such
security is listed or traded as reported by Bloomberg.

        (e)     [Intentionally Omitted.]

        (f)     "Custodian" means any receiver, trustee, assignee, liquidator or
similar official under any Bankruptcy Law.

        (g)     "Floor Price" means initially $0.50, which amount may be
increased or decreased from time to time as provided below, except that in no
case shall the Floor Price be less than $0.20. The Company may at any time give
written notice (a "Floor Price Change Notice") to the Buyer increasing or
decreasing the Floor Price. The Floor Price Change Notice shall be effective
only for purchases that have a Purchase Date later than one (1) Trading Day
after receipt of the Floor Price Change Notice by the Buyer. Any purchase by the
Buyer that has a Purchase Date on or prior to the first Trading Day after
receipt of a Floor Price Change Notice from the Company must be honored by the
Company as otherwise provided herein. The Floor Price shall be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock
split or other similar transaction.

        (h)     "Maturity Date" means the date that is 500 Trading Days (25
Monthly Periods) from the Commencement Date.

        (i)     "Monthly Period" means each successive 20 Trading Day period
commencing with the Commencement Date.

        (j)     "Person" means an individual or entity including any limited
liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization and a government or any department or agency
thereof.

        (k)     "Principal Market" means the Nasdaq OTC Bulletin Board; provided
however, that in the event the Company's Common Stock is ever listed or traded
on the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock
Exchange or the American Stock Exchange, than the "Principal

                                       17

<PAGE>

Market" shall mean such other market or exchange on which the Company's Common
Stock is then listed or traded.

        (l)     "Purchase Amount" means the portion of the Available Amount to
be purchased by the Buyer pursuant to Section 1 hereof.

        (m)     "Purchase Date" means the actual date that the Buyer is to buy
Purchase Shares pursuant to Section 1 hereof.

        (n)     "Purchase Price" means, as of any date of determination the
lower of the (A) the lowest Sale Price of the Common Stock on such date of
determination and (B) the arithmetic average of the three (3) lowest Closing
Sale Prices for the Common Stock during the Twelve (12) consecutive Trading Days
ending on the Trading Day immediately preceding such date of determination (to
be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction).

        (o)     "Sale Price" means, for any security as of any date, any trade
price for such security (other than in a trade effected by the Buyer or any of
its affiliates) on the Principal Market as reported by Bloomberg, or, if the
Principal Market is not the principal securities exchange or trading market for
such security, the trade price of such security on the principal securities
exchange or trading market where such security is listed or traded as reported
by Bloomberg.

        (p)     "SEC" means the United States Securities and Exchange
Commission.

        (q)     "Transfer Agent" means the transfer agent of the Company as set
forth in Section 11(f) hereof or such other person who is then serving as the
transfer agent for the Company in respect of the Common Stock.

        (r)     "Trading Day" means any day on which the Principal Market is
open for customary trading.

        11.     MISCELLANEOUS.

        (a)     Governing Law; Jurisdiction; Jury Trial. The corporate laws of
the State of Delaware shall govern all issues concerning the relative rights of
the Company and its shareholders. All other questions concerning the
construction, validity, enforcement and interpretation of this Agreement and the
other Transaction Documents shall be governed by the internal laws of the State
of Illinois, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of Illinois or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of Illinois. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of Chicago, for
the adjudication of any dispute hereunder or under the other Transaction
Documents or in connection herewith or therewith, or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such
suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to such party at the
address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. EACH PARTY

                                       18

<PAGE>

HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A
JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY.

        (b)     Counterparts. This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party; provided that a facsimile signature
shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not
a facsimile signature.

        (c)     Headings. The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.

        (d)     Severability. If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction.

        (e)     Entire Agreement; Amendments. With the exception of the Mutual
Nondisclosure Agreement between the parties dated as of October 13, 2000, this
Agreement supersedes all other prior oral or written agreements between the
Buyer, the Company, their affiliates and persons acting on their behalf with
respect to the matters discussed herein, and this Agreement, the other
Transaction Documents and the instruments referenced herein contain the entire
understanding of the parties with respect to the matters covered herein and
therein and, except as specifically set forth herein or therein, neither the
Company nor the Buyer makes any representation, warranty, covenant or
undertaking with respect to such matters. No provision of this Agreement may be
amended other than by an instrument in writing signed by the Company and the
Buyer, and no provision hereof may be waived other than by an instrument in
writing signed by the party against whom enforcement is sought.

        (f)     Notices. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Trading Day after deposit with
a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be:

        If to the Company:
                Unigene Laboratories, Inc.

                110 Little Falls Road
                Fairfield, NJ 07004
                Telephone:   973-882-0860
                Facsimile:   973-227-6088
                Attention:   Chief Executive Officer

        With a copy to:

                Dechert LLP
                4000 Bell Atlantic Tower

                                       19

<PAGE>

                1717 Arch Street
                Philadelphia, PA  19103
                Telephone:   215-994-4000
                Facsimile:   215-994-2222
                Attention:   Christopher G. Karras, Esq.

        If to the Buyer:
                Fusion Capital Fund II, LLC
                222 Merchandise Mart Plaza, Suite 9-112
                Chicago, IL 60654
                Telephone:   312-644-6644
                Facsimile:   312-644-6244
                Attention:   Steven G. Martin

        If to the Transfer Agent:
                Registrar & Transfer Company
                10 Commerce Drive
                Cranford, NJ 07016
                Telephone:   908-497-2300
                Facsimile:   908-497-2310
                Attention:   Ms. Florence Bogaenko:

or at such other address and/or facsimile number and/or to the attention of such
other person as the recipient party has specified by written notice given to
each other party three (3) Trading Days prior to the effectiveness of such
change. Written confirmation of receipt (A) given by the recipient of such
notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, and recipient facsimile number or (C) provided by a nationally recognized
overnight delivery service, shall be rebuttable evidence of personal service,
receipt by facsimile or receipt from a nationally recognized overnight delivery
service in accordance with clause (i), (ii) or (iii) above, respectively.

        (g)     Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their respective successors and assigns.
The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Buyer, including by merger or
consolidation. The Buyer may not assign its rights or obligations under this
Agreement.

        (h)     No Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other person.

        (i)     Publicity. The Buyer shall have the right to approve before
issuance any press releases or any other public disclosure (including any
filings with the SEC) with respect to the transactions contemplated hereby;
provided, however, that the Company shall be entitled, without the prior
approval of the Buyer, to make any press release or other public disclosure
(including any filings with the SEC) with respect to such transactions as is
required by applicable law and regulations (although the Buyer shall be
consulted by the Company in connection with any such press release or other
public disclosure prior to its release and shall be provided with a copy
thereof).

        (j)     Further Assurances. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and

                                       20

<PAGE>

accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

        (k)     Termination. This Agreement may be terminated only as follows:

                (i)     By the Buyer any time an Event of Default exists without
        any liability or payment to the Company. However, if pursuant to or
        within the meaning of any Bankruptcy Law, the Company commences a
        voluntary case or any Person commences a proceeding against the Company,
        a Custodian is appointed for the Company or for all or substantially all
        of its property, or the Company makes a general assignment for the
        benefit of its creditors, (any of which would be an Event of Default as
        described in Sections 9(g), 9(h) and 9(i) hereof) this Agreement shall
        automatically terminate without any liability or payment to the Company
        without further action or notice by any Person. No such termination of
        this Agreement under this Section 11(k)(i) shall affect the Company's or
        the Buyer's obligations under this Agreement with respect to pending
        purchases and the Company and the Buyer shall complete their respective
        obligations with respect to any pending purchases under this Agreement.

                (ii)    In the event that the Commencement shall not have
        occurred, the Company shall have the option to terminate this Agreement
        for any reason or for no reason without liability of any party to any
        other party.

                (iii)   In the event that the Commencement shall not have
        occurred on or before January 30, 2004, due to the failure to satisfy
        the conditions set forth in Sections 6 and 7 above with respect to the
        Commencement (and the nonbreaching party's failure to waive such
        unsatisfied condition(s)), the nonbreaching party shall have the option
        to terminate this Agreement at the close of business on such date or
        thereafter without liability of any party to any other party.

                (iv)    If by the Maturity Date (including any extension thereof
        by the Company pursuant to Section 10(g) hereof), for any reason or for
        no reason the full Available Amount under this Agreement has not been
        purchased as provided for in Section 1 of this Agreement, by the Buyer
        without any liability or payment to the Company.

                (v)     At any time after the Commencement Date, the Company
        shall have the option to terminate this Agreement for any reason or for
        no reason by delivering notice (a "Company Termination Notice") to the
        Buyer electing to terminate this Agreement without any liability or
        payment to the Buyer. The Company Termination Notice shall not be
        effective until one (1) Trading Day after it has been received by the
        Buyer.

                (vi)    This Agreement shall automatically terminate on the date
        that the Company sells and the Buyer purchases the full Available Amount
        as provided herein, without any action or notice on the part of any
        party.

Except as set forth in Sections 11(k)(i) (in respect of an Event of Default
under Sections 9(g), 9(h) and 9(i)) and 11(k)(vi), any termination of this
Agreement pursuant to this Section 11(k) shall be effected by written notice
from the Company to the Buyer, or the Buyer to the Company, as the case may be,
setting forth the basis for the termination hereof. The representations and
warranties of the Company and the Buyer contained in Sections 2 and 3 hereof,
the indemnification provisions set forth in Section 8 hereof and the agreements
and covenants set forth in Section 11, shall survive the Commencement and any
termination of this Agreement. No termination of this Agreement shall affect the
Company's or the Buyer's obligations under this Agreement with respect to
pending purchases and the Company and the

                                       21

<PAGE>

Buyer shall complete their respective obligations with respect to any pending
purchases under this Agreement.

        (l)     No Financial Advisor, Placement Agent, Broker or Finder. The
Company represents and warrants to the Buyer that it has not engaged any
financial advisor, placement agent, broker or finder in connection with the
transactions contemplated hereby. The Buyer represents and warrants to the
Company that it has not engaged any financial advisor, placement agent, broker
or finder in connection with the transactions contemplated hereby.

        (m)     No Strict Construction. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.

        (n)     Remedies, Other Obligations, Breaches and Injunctive Relief. The
Buyer's remedies provided in this Agreement shall be cumulative and in addition
to all other remedies available to the Buyer under this Agreement, at law or in
equity (including a decree of specific performance and/or other injunctive
relief), no remedy of the Buyer contained herein shall be deemed a waiver of
compliance with the provisions giving rise to such remedy and nothing herein
shall limit the Buyer's right to pursue actual damages for any failure by the
Company to comply with the terms of this Agreement. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to
the Buyer and that the remedy at law for any such breach may be inadequate. The
Company therefore agrees that, in the event of any such breach or threatened
breach, the Buyer shall be entitled, in addition to all other available
remedies, to an injunction restraining any breach, without the necessity of
showing economic loss and without any bond or other security being required.

        (o)     Changes to the Terms of this Agreement. This Agreement and any
provision hereof may only be amended by an instrument in writing signed by the
Company and the Buyer. The term "Agreement" and all reference thereto, as used
throughout this instrument, shall mean this instrument as originally executed,
or if later amended or supplemented, then as so amended or supplemented.

        (p)     Enforcement Costs. If: (i) this Agreement is placed by the Buyer
in the hands of an attorney for enforcement or is enforced by the Buyer through
any legal proceeding; or (ii) an attorney is retained to represent the Buyer in
any bankruptcy, reorganization, receivership or other proceedings affecting
creditors' rights and involving a claim under this Agreement; or (iii) an
attorney is retained to represent the Buyer in any other proceedings whatsoever
arising out of entering into, performance under or enforcement of, this
Agreement, then the Company shall pay to the Buyer, as incurred by the Buyer,
all reasonable costs and expenses including attorneys' fees incurred in
connection therewith, in addition to all other amounts due hereunder.

        (q)     Failure or Indulgence Not Waiver. No failure or delay in the
exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right,
power or privilege.

                                    * * * * *

                                       22

<PAGE>

        IN WITNESS WHEREOF, the Buyer and the Company have caused this Common
Stock Purchase Agreement to be duly executed as of the date first written above.

                                        THE COMPANY:

                                        UNIGENE LABORATORIES, INC.

                                        By:
                                           ----------------------------------
                                        Name: Warren P. Levy
                                        Title: Chief Executive Officer

                                        BUYER:

                                        FUSION CAPITAL FUND II, LLC
                                        BY: FUSION CAPITAL PARTNERS, LLC

                                        BY: SGM HOLDINGS CORP.

                                        By:
                                           ----------------------------------
                                        Name: Steven G. Martin
                                        Title: President

                                       23

<PAGE>

                                    SCHEDULES

Schedule 3(a)           Subsidiaries
Schedule 3(c)           Capitalization
Schedule 3(e)           Conflicts
Schedule 3(f)           1934 Act Filings
Schedule 3(g)           Material Changes
Schedule 3(h)           Litigation
Schedule 3(l)           Intellectual Property
Schedule 3(n)           Liens
Schedule 3(r)           Certain Transactions
Schedule 9(f)           Certain Indebtedness

                                    EXHIBITS

Exhibit A               Form of Company Counsel Opinion
Exhibit B               Form of Officer's Certificate
Exhibit C               Form of Resolutions of Board of Directors of the Company
Exhibit D               Form of Secretary's Certificate
Exhibit E               Form of Letter to Transfer Agent
Exhibit F               Form of Warrant

<PAGE>

                              DISCLOSURE SCHEDULES

                          Schedule 3(a) - Subsidiaries

                         Schedule 3(c) - Capitalization

                          Schedule 3(e) - No Conflicts

                        Schedule 3(f) - 1934 Act Filings

                   Schedule 3(g) - Absence of Certain Changes

                           Schedule 3(h) - Litigation

                  Schedule 3(l) - Intellectual Property Rights

                              Schedule 3(n) - Title

                  Schedule 3(r) - Transactions with Affiliates

                      Schedule 9(f) - Certain Indebtedness

<PAGE>

                                    EXHIBIT A

FORM OF COMPANY COUNSEL OPINION

        Capitalized terms used herein but not defined herein, have the meaning
set forth in the Common Stock Purchase Agreement. Based on the foregoing, and
subject to the assumptions and qualifications set forth herein, we are of the
opinion that:

                1. The Company is a corporation existing and in good standing
under the laws of the State of Delaware. The Company is qualified to do business
as a foreign corporation and is in good standing in the States of New Jersey,
Delaware.

                2. The Company has the corporate power to execute and deliver,
and perform its obligations under, each Transaction Document to which it is a
party. The Company has the corporate power to conduct its business as, to the
best of our knowledge, it is now conducted, and to own and use the properties
owned and used by it.

                3. The execution, delivery and performance by the Company of the
Transaction Documents to which it is a party have been duly authorized by all
necessary corporate action on the part of the Company. The execution and
delivery of the Transaction Documents by the Company, the performance of the
obligations of the Company thereunder and the consummation by it of the
transactions contemplated therein have been duly authorized and approved by the
Company's Board of Directors and no further consent, approval or authorization
of the Company, its Board of Directors or its stockholders is required. The
Transaction Documents to which the Company is a party have been duly executed
and delivered by the Company and are the valid and binding obligations of the
Company, enforceable against the Company in accordance with their terms except
as such enforceability may be limited by general principles of equity or
applicable bankruptcy, insolvency, liquidation or similar laws relating to, or
affecting creditor's rights and remedies.

                4. The execution, delivery and performance by the Company of the
Transaction Documents, the consummation by the Company of the transactions
contemplated thereby including the offering, sale and issuance of the Commitment
Shares, and the Purchase Shares in accordance with the terms and conditions of
the Common Stock Purchase Agreement, and fulfillment and compliance with terms
of the Transaction Documents, does not and shall not: (i) conflict with,
constitute a breach of or default (or an event which, with the giving of notice
or lapse of time or both, constitutes or could constitute a breach or a
default), under (a) the Certificate of Incorporation or the Bylaws of the
Company, (b) any material agreement, note, lease, mortgage, deed or other
material instrument to which to our knowledge the Company is a party or by which
the Company or any of its assets are bound, (ii) result in any violation of any
statute, law, rule or regulation applicable to the Company, or (iii) to our
knowledge, violate any order, writ, injunction or decree applicable to the
Company or any of its subsidiaries.

                5. The issuance of the Purchase Shares, Warrants, Warrant Shares
and Commitment Shares pursuant to the terms and conditions of the Transaction
Documents has been duly authorized and the Warrants and Commitment Shares are
validly issued, fully paid and non-assessable, to our knowledge, free of all
taxes, liens, charges, restrictions, rights of first refusal and preemptive
rights. ________ shares of Common Stock have been properly reserved for issuance
under the Common Stock Purchase Agreement. When issued and paid for in
accordance with the Common Stock Purchase Agreement, the Purchase Shares shall
be validly issued, fully paid and non-assessable, to our knowledge, free of all
taxes, liens, charges, restrictions, rights of first refusal and preemptive
rights. 500,000 shares of Common Stock have been properly reserved for issuance
as Warrant Shares under the Common Stock Purchase

<PAGE>

Agreement. When issued in accordance with the Warrant, the Warrant Shares shall
be validly issued, fully paid and non-assessable, to our knowledge, free of all
taxes, liens, charges, restrictions, rights of first refusal and preemptive
rights. To our knowledge, the execution and delivery of the Registration Rights
Agreement do not, and the performance by the Company of its obligations
thereunder shall not, give rise to any rights of any other person for the
registration under the Securities Act of any shares of Common Stock or other
securities of the Company which have not been waived.

                6. As of the date hereof, the authorized capital stock of the
Company consists of _______ shares of common stock, par value $______ per share,
of which to our knowledge __________ shares are issued and outstanding. Except
as set forth on Schedule 3(c) of the Common Stock Purchase Agreement, to our
knowledge, there are no outstanding shares of capital stock or other securities
convertible into or exchangeable or exercisable for shares of the capital stock
of the Company.

                7. Assuming the accuracy of the representations and your
compliance with the covenants made by you in the Transaction Documents, the
offering, sale and issuance of the Commitment Shares to you pursuant to the
Transaction Documents is exempt from registration under the 1933 Act and the
securities laws and regulations of the States of Delaware, New York, New Jersey,
Illinois.

                8. Other than that which has been obtained and completed prior
to the date hereof, no authorization, approval, consent, filing or other order
of any federal or state governmental body, regulatory agency, or stock exchange
or market, or any court, or, to our knowledge, any third party is required to be
obtained by the Company to enter into and perform its obligations under the
Transaction Documents or for the Company to issue and sell the Purchase Shares
as contemplated by the Transaction Documents.

                9. The Common Stock is registered pursuant to Section 12(g) of
the 1934 Act. To our knowledge, since January 1, 2002, the Company has been in
compliance with the reporting requirements of the 1934 Act applicable to it. To
our knowledge, since January 1, 2002, the Company has not received any written
notice from the Principal Market stating that the Company has not been in
compliance with any of the rules and regulations (including the requirements for
continued listing) of the Principal Market.

        We further advise you that to our knowledge, except as disclosed on
Schedule 3(h) in the Common Stock Purchase Agreement, there is no action, suit,
proceeding, inquiry or investigation before or by any court, public board or
body, any governmental agency, any stock exchange or market, or self-regulatory
organization, which has been threatened in writing or which is currently pending
against the Company, any of its subsidiaries, any officers or directors of the
Company or any of its subsidiaries or any of the properties of the Company or
any of its subsidiaries.

        In addition, we have participated in the preparation of the Registration
Statement (SEC File #________) covering the sale of the Purchase Shares, the
Commitment Shares including the prospectus dated ____________, contained therein
and in conferences with officers and other representatives of the Company
(including the Company's independent auditors) during which the contents of the
Registration Statement and related matters were discussed and reviewed and,
although we are not passing upon and do not assume any responsibility for the
accuracy, completeness or fairness of the statements contained in the
Registration Statement, on the basis of the information that was developed in
the course of the performance of the services referred to above, considered in
the light of our understanding of the applicable law, nothing came to our
attention that caused us to believe that the Registration Statement (other than
the financial statements and schedules and the other financial and statistical
data included therein, as to which we express no belief), as of their dates,
contained any untrue statement of a material

<PAGE>

fact or omitted to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading.

<PAGE>

                                    EXHIBIT B

FORM OF OFFICER'S CERTIFICATE

                This Officer's Certificate ("Certificate") is being delivered
pursuant to Section 7(e) of that certain Common Stock Purchase Agreement dated
as of _________, ("Common Stock Purchase Agreement"), by and between UNIGENE
LABORATORIES, INC., a Delaware corporation (the "Company"), and FUSION CAPITAL
FUND II, LLC (the "Buyer"). Terms used herein and not otherwise defined shall
have the meanings ascribed to them in the Common Stock Purchase Agreement.

                The undersigned, ___________, ______________ of the Company,
hereby certifies as follows:

                1.      I am the _____________ of the Company and make the
        statements contained in this Certificate;

                2.      The representations and warranties of the Company are
        true and correct in all material respects (except to the extent that any
        of such representations and warranties is already qualified as to
        materiality in Section 3 of the Common Stock Purchase Agreement, in
        which case, such representations and warranties are true and correct
        without further qualification) as of the date when made and as of the
        Commencement Date as though made at that time (except for
        representations and warranties that speak as of a specific date);

                3.      The Company has performed, satisfied and complied in all
        material respects with covenants, agreements and conditions required by
        the Transaction Documents to be performed, satisfied or complied with by
        the Company at or prior to the Commencement Date.

                4.      The Company has not taken any steps, and does not
        currently expect to take any steps, to seek protection pursuant to any
        Bankruptcy Law nor does the Company or any of its Subsidiaries have any
        knowledge or reason to believe that its creditors intend to initiate
        involuntary bankruptcy or insolvency proceedings.

        IN WITNESS WHEREOF, I have hereunder signed my name on this ___ day of
___________.

                                        ----------------------
                                        Name:
                                        Title:

        The undersigned as Secretary of ________, a ________ corporation, hereby
certifies that ___________ is the duly elected, appointed, qualified and acting
________ of _________ and that the signature appearing above is his genuine
signature.

                                           ---------------------------------
                                           Secretary

<PAGE>

                                   EXHIBIT C-1

                           FORM OF COMPANY RESOLUTIONS

                         FOR SIGNING PURCHASE AGREEMENT

                          UNANIMOUS WRITTEN CONSENT OF

                           UNIGENE LABORATORIES, INC.

        Pursuant to Section ______ of the _________ [DGCL], the undersigned,
being all of the directors of UNIGENE LABORATORIES, INC., a Delaware corporation
(the "Corporation") do hereby consent to and adopt the following resolutions as
the action of the Board of Directors for and on behalf of the Corporation and
hereby direct that this Consent be filed with the minutes of the proceedings of
the Board of Directors:

        WHEREAS, there has been presented to the Board of Directors of the
Corporation a draft of the Common Stock Purchase Agreement (the "Purchase
Agreement") by and between the Corporation and Fusion Capital Fund II, LLC
("Fusion"), providing for the purchase by Fusion of up to Fifteen Million
Dollars ($15,000,000) of the Corporation's common stock, par value $0.01 (the
"Common Stock"); and

        WHEREAS, after careful consideration of the Purchase Agreement, the
documents incident thereto and other factors deemed relevant by the Board of
Directors, the Board of Directors has determined that it is advisable and in the
best interests of the Corporation to engage in the transactions contemplated by
the Purchase Agreement, including, but not limited to, the issuance to Fusion of
1,000,000 shares of Common Stock as a commitment fee (the "Commitment Shares")
and warrants (the "Warrants") to purchase 500,000 shares of Common Stock and the
sale of shares of Common Stock to Fusion up to the available amount under the
Purchase Agreement (the "Purchase Shares").

                              TRANSACTION DOCUMENTS

        NOW, THEREFORE, BE IT RESOLVED, that the transactions described in the
Purchase Agreement are hereby approved and _____________________________________
(the "Authorized Officers") are severally authorized to execute and deliver the
Purchase Agreement, and any other agreements or documents contemplated thereby
including, without limitation, a registration rights agreement (the
"Registration Rights Agreement") providing for the registration of the shares of
the Company's Common Stock issuable in respect of the Purchase Agreement on
behalf of the Corporation, with such amendments, changes, additions and
deletions as the Authorized Officers may deem to be appropriate and approve on
behalf of, the Corporation, such approval to be conclusively evidenced by the
signature of an Authorized Officer thereon; and

        FURTHER RESOLVED, that the terms and provisions of the Registration
Rights Agreement by and among the Corporation and Fusion are hereby approved and
the Authorized Officers are authorized to execute and deliver the Registration
Rights Agreement (pursuant to the terms of the Purchase Agreement), with such
amendments, changes, additions and deletions as the Authorized Officer may deem
appropriate and approve on behalf of, the Corporation, such approval to be
conclusively evidenced by the signature of an Authorized Officer thereon; and

<PAGE>

        FURTHER RESOLVED, that the terms and provisions of the Form of Transfer
Agent Instructions (the "Instructions") are hereby approved and the Authorized
Officers are authorized to execute and deliver the Instructions (pursuant to the
terms of the Purchase Agreement), with such amendments, changes, additions and
deletions as the Authorized Officers may deem appropriate and approve on behalf
of, the Corporation, such approval to be conclusively evidenced by the signature
of an Authorized Officer thereon; and

                         EXECUTION OF PURCHASE AGREEMENT

        FURTHER RESOLVED, that the Corporation be and it hereby is authorized to
execute the Purchase Agreement providing for the purchase of common stock of the
Corporation having an aggregate value of up to $15,000,000; and

                      ISSUANCE OF COMMON STOCK AND WARRANTS

        FURTHER RESOLVED, that the Corporation is hereby authorized to issue
1,000,000 shares of Common Stock to Fusion Capital Fund II, LLC as Commitment
Shares and that upon issuance of the Commitment Shares pursuant to the Purchase
Agreement, the Commitment Shares shall be duly authorized, validly issued, fully
paid and nonassessable with no personal liability attaching to the ownership
thereof; and

        FURTHER RESOLVED, that the Corporation is hereby authorized to issue
shares of Common Stock upon the purchase of Purchase Shares up to the available
amount under the Purchase Agreement in accordance with the terms of the Purchase
Agreement and that, upon issuance of the Purchase Shares pursuant to the
Purchase Agreement, the Purchase Shares will be duly authorized, validly issued,
fully paid and nonassessable with no personal liability attaching to the
ownership thereof; and

     FURTHER RESOLVED, that the Corporation shall initially reserve 8,500,000
shares of Common Stock for issuance as Purchase Shares under the Purchase
Agreement.

                FURTHER RESOLVED, that the Corporation is hereby authorized to
issue the Warrants to purchase the Warrant Shares and that, upon issuance of the
Warrant Shares pursuant to the terms of the Warrants, the Warrant Shares will be
duly authorized, validly issued, fully paid and nonassessable with no personal
liability attaching to the ownership thereof; and

                FURTHER RESOLVED, that the Corporation shall initially reserve
500,000 shares of Common Stock (subject to equitable adjustment for any
reorganization, recapitalization, non-cash dividend, stock split or other
similar transaction) for issuance as Warrant Shares under the Warrants.

        (1) Approval of Actions

        FURTHER RESOLVED, that, without limiting the foregoing, the Authorized
Officers are, and each of them hereby is, authorized and directed to proceed on
behalf of the Corporation and to take all such steps as deemed necessary or
appropriate, with the advice and assistance of counsel, to cause the Corporation
to consummate the agreements referred to herein and to perform its obligations
under such agreements; and

        FURTHER RESOLVED, that the Authorized Officers be, and each of them
hereby is, authorized, empowered and directed on behalf of and in the name of
the Corporation, to take or cause to be taken all such further actions and to
execute and deliver or cause to be executed and delivered all such further
agreements, amendments, documents, certificates, reports, schedules,
applications, notices, letters and undertakings and to incur and pay all such
fees and expenses as in their judgment shall be necessary, proper or desirable
to carry into effect the purpose and intent of any and all of the foregoing
resolutions,

<PAGE>

and that all actions heretofore taken by any officer or director of the
Corporation in connection with the transactions contemplated by the agreements
described herein are hereby approved, ratified and confirmed in all respects.

        IN WITNESS WHEREOF, the Board of Directors has executed and delivered
this Consent effective as of __________, 2003.

------------------------

------------------------

------------------------

being all of the directors of UNIGENE LABORATORIES, INC.

<PAGE>

                                   EXHIBIT C-2

          FORM OF COMPANY RESOLUTIONS APPROVING REGISTRATION STATEMENT

                          UNANIMOUS WRITTEN CONSENT OF

                           UNIGENE LABORATORIES, INC.

        Pursuant to Section ______ of the _________ [DGCL], the undersigned,
being all of the directors of UNIGENE LABORATORIES, INC., a Delaware corporation
(the "Corporation") do hereby consent to and adopt the following resolutions as
the action of the Board of Directors for and on behalf of the Corporation and
hereby direct that this Consent be filed with the minutes of the proceedings of
the Board of Directors.

                        WHEREAS, there has been presented to the Board of
Directors of the Corporation a Common Stock Purchase Agreement (the "Purchase
Agreement") by and among the Corporation and Fusion Capital Fund II, LLC
("Fusion"), providing for the purchase by Fusion of up to Fifteen Million
Dollars ($15,000,000) of the Corporation's common stock, par value $0.01 (the
"Common Stock"); and

        WHEREAS, after careful consideration of the Purchase Agreement, the
documents incident thereto and other factors deemed relevant by the Board of
Directors, the Board of Directors has approved the Purchase Agreement and the
transactions contemplated thereby and the Company has executed and delivered the
Purchase Agreement to Fusion; and

        WHEREAS, in connection with the transactions contemplated pursuant to
the Purchase Agreement, the Company has agreed to file a registration statement
with the Securities and Exchange Commission (the "Commission") registering the
Commitment Shares, Warrant Shares and the Purchase Shares (each, as defined in
the Purchase Agreement) and to list the Commitment Shares, Warrant Shares and
Purchase Shares on the Nasdaq Over-the-Counter Bulletin Board, as applicable;

                WHEREAS, the management of the Corporation has prepared an
initial draft of a Registration Statement on Form ___ (the "Registration
Statement") in order to register the sale of the Purchase Shares, Warrant Shares
and the Commitment Shares (collectively, the "Shares"); and

        WHEREAS, the Board of Directors has determined to approve the
Registration Statement and to authorize the appropriate officers of the
Corporation to take all such actions as they may deem appropriate to effect the
offering.

        NOW, THEREFORE, BE IT RESOLVED, that the officers and directors of the
Corporation be, and each of them hereby is, authorized and directed, with the
assistance of counsel and accountants for the Corporation, to prepare, execute
and file with the Commission the Registration Statement, which Registration
Statement shall be filed substantially in the form presented to the Board of
Directors, with such changes therein as the Chief Executive Officer of the
Corporation or any Vice President of the Corporation shall deem desirable and in
the best interest of the Corporation and its shareholders (such

<PAGE>

officer's execution thereof including such changes shall be deemed to evidence
conclusively such determination); and

        FURTHER RESOLVED, that the officers of the Corporation be, and each of
them hereby is, authorized and directed, with the assistance of counsel and
accountants for the Corporation, to prepare, execute and file with the
Commission all amendments, including post-effective amendments, and supplements
to the Registration Statement, and all certificates, exhibits, schedules,
documents and other instruments relating to the Registration Statement, as such
officers shall deem necessary or appropriate (such officer's execution and
filing thereof shall be deemed to evidence conclusively such determination); and

        FURTHER RESOLVED, that the execution of the Registration Statement and
of any amendments and supplements thereto by the officers and directors of the
Corporation be, and the same hereby is, specifically authorized either
personally or by the Authorized Officers as such officer's or director's true
and lawful attorneys-in-fact and agents; and

        FURTHER RESOLVED, that the Authorized Officers are hereby designated as
"Agent for Service" of the Corporation in connection with the Registration
Statement and the filing thereof with the Commission, and the Authorized
Officers hereby are authorized to receive communications and notices from the
Commission with respect to the Registration Statement; and

        FURTHER RESOLVED, that the officers of the Corporation be, and each of
them hereby is, authorized and directed to pay all fees, costs and expenses that
may be incurred by the Corporation in connection with the Registration
Statement; and

        FURTHER RESOLVED, that it is desirable and in the best interest of the
Corporation that the Shares be qualified or registered for sale in various
states; that the officers of the Corporation be, and each of them hereby is,
authorized to determine the states in which appropriate action shall be taken to
qualify or register for sale all or such part of the Shares as they may deem
advisable; that said officers be, and each of them hereby is, authorized to
perform on behalf of the Corporation any and all such acts as they may deem
necessary or advisable in order to comply with the applicable laws of any such
states, and in connection therewith to execute and file all requisite papers and
documents, including, but not limited to, applications, reports, surety bonds,
irrevocable consents, appointments of attorneys for service of process and
resolutions; and the execution by such officers of any such paper or document or
the doing by them of any act in connection with the foregoing matters shall
conclusively establish their authority therefor from the Corporation and the
approval and ratification by the Corporation of the papers and documents so
executed and the actions so taken; and

        FURTHER RESOLVED, that if, in any state where the securities to be
registered or qualified for sale to the public, or where the Corporation is to
be registered in connection with the public offering of the Shares, a prescribed
form of resolution or resolutions is required to be adopted by the Board of
Directors, each such resolution shall be deemed to have been and hereby is
adopted, and the Secretary is hereby authorized to certify the adoption of all
such resolutions as though such resolutions were now presented to and adopted by
the Board of Directors; and

        FURTHER RESOLVED, that the officers of the Corporation with the
assistance of counsel be, and each of them hereby is, authorized and directed to
take all necessary steps and do all other things necessary and appropriate to
effect the listing of the Shares on the Nasdaq Over-the-Counter Bulletin Board,
as applicable.

<PAGE>

                               APPROVAL OF ACTIONS

        FURTHER RESOLVED, that, without limiting the foregoing, the Authorized
Officers are, and each of them hereby is, authorized and directed to proceed on
behalf of the Corporation and to take all such steps as are deemed necessary or
appropriate, with the advice and assistance of counsel, to cause the Corporation
to take all such action referred to herein and to perform its obligations
incident to the registration, listing and sale of the Shares; and

        FURTHER RESOLVED, that the Authorized Officers be, and each of them
hereby is, authorized, empowered and directed on behalf of and in the name of
the Corporation, to take or cause to be taken all such further actions and to
execute and deliver or cause to be executed and delivered all such further
agreements, amendments, documents, certificates, reports, schedules,
applications, notices, letters and undertakings and to incur and pay all such
fees and expenses as in their judgment shall be necessary, proper or desirable
to carry into effect the purpose and intent of any and all of the foregoing
resolutions, and that all actions heretofore taken by any officer or director of
the Corporation in connection with the transactions contemplated by the
agreements described herein are hereby approved, ratified and confirmed in all
respects.

                IN WITNESS WHEREOF, the Board of Directors has executed and
delivered this Consent effective as of __________, 200_.

------------------------

------------------------

------------------------

being all of the directors of UNIGENE LABORATORIES, INC.

<PAGE>

                                    EXHIBIT D

                         FORM OF SECRETARY'S CERTIFICATE

        This Secretary's Certificate ("Certificate") is being delivered pursuant
to Section 7(k) of that certain Common Stock Purchase Agreement dated as of
__________, ("Common Stock Purchase Agreement"), by and between UNIGENE
LABORATORIES, INC., a Delaware corporation (the "Company") and FUSION CAPITAL
FUND II, LLC (the "Buyer"), pursuant to which the Company may sell to the Buyer
up to Fifteen Million Dollars ($15,000,000) of the Company's Common Stock, par
value $0.01 per share (the "Common Stock"). Terms used herein and not otherwise
defined shall have the meanings ascribed to them in the Common Stock Purchase
Agreement.

        The undersigned, ____________, Secretary of the Company, hereby
certifies as follows:

                1.      I am the Secretary of the Company and make the
        statements contained in this Secretary's Certificate.

                2.      Attached hereto as Exhibit A and Exhibit B are true,
        correct and complete copies of the Company's bylaws ("Bylaws") and
        Certificate of Incorporation ("Articles"), in each case, as amended
        through the date hereof, and no action has been taken by the Company,
        its directors, officers or shareholders, in contemplation of the filing
        of any further amendment relating to or affecting the Bylaws or
        Articles.

                3.      Attached hereto as Exhibit C are true, correct and
        complete copies of the resolutions duly adopted by the Board of
        Directors of the Company on _____________, at which a quorum was present
        and acting throughout. Such resolutions have not been amended, modified
        or rescinded and remain in full force and effect and such resolutions
        are the only resolutions adopted by the Company's Board of Directors, or
        any committee thereof, or the shareholders of the Company relating to or
        affecting (i) the entering into and performance of the Common Stock
        Purchase Agreement, or the issuance, offering and sale of the Purchase
        Shares and the Commitment Shares and (ii) and the performance of the
        Company of its obligation under the Transaction Documents as
        contemplated therein.

4.      As of the date hereof, the authorized, issued and reserved capital stock
of the Company is as set forth on Exhibit D hereto.

        IN WITNESS WHEREOF, I have hereunder signed my name on this ___ day of
____________.

                             ----------------------
                                    Secretary

The undersigned as ___________ of __________, a ________ corporation, hereby
certifies that ____________ is the duly elected, appointed, qualified and acting
Secretary of _________, and that the signature appearing above is his genuine
signature.

                             -------------------------------

<PAGE>

                                    EXHIBIT E

          FORM OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE
             COMMITMENTS SHARES AT SIGNING OF THE PURCHASE AGREEMENT

                              [COMPANY LETTERHEAD]

[DATE]

[TRANSFER AGENT]

----------------

----------------

----------------

Re: Issuance of Common Shares to Fusion Capital Fund II, LLC

Dear ________,

On behalf of ______________, (the "Company"), you are hereby instructed to issue
as soon as possible 1,000,000 shares of our common stock in the name of Fusion
Capital Fund II, LLC. The share certificate should be dated [DATE OF THE COMMON
STOCK PURCHASE AGREEMENT]. I have included a true and correct copy of a
unanimous written consent executed by all of the members of the Board of
Directors of the Company adopting resolutions approving the issuance of these
shares. The shares should be issued subject to the following restrictive legend:

        "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
        UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
        SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND
        MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE
        ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
        THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
        LAWS, OR AN OPINION OF BUYER'S COUNSEL, IN A CUSTOMARY FORM, THAT
        REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
        SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT."

<PAGE>

The share certificate should be sent as soon as possible via overnight mail to
the following address:

                        Fusion Capital Fund II, LLC
                        222 Merchandise Mart Plaza, Suite 9-112
                        Chicago, IL 60654
                        Attention: Steven Martin

Thank you very much for your help. Please call me at ______________ if you have
any questions or need anything further.

UNIGENE LABORATORIES, INC.

BY:
   -------------------------------
      [name]
      [title]

<PAGE>

                                    EXHIBIT F

                                 FORM OF WARRANT

        [Sent Separately]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]